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include i) a low redox potential which allows radiation 
induced solvated electrons to flow to texaphyrin rather than 
neutralizing hydroxyl radicals, allowing the hydroxyl radi 
cals to cause cellular damage, ii) a relatively stable texa 
phyrin radical which, nevertheless, reacts readily to 
covalently modify neighboring molecules causing further 
cellular damage, and iii) intrinsic biolocalization and indif 
ference to the presence of O, which allow texaphyrin to be 
particularly effective for treating the hypoxic areas of solid 
tumors. Sensitizer enhancement ratios of 1.62 and 2.2 were 
achieved at 20 M and 80 uM gadolinium-texaphyrin, 
respectively, with a mouse leukemia cell line. Methods of 
treatment for an individual having a tumor include the use of 
a texaphyrin as a radiosensitizer and as an agent for photo 
dynamic tumor therapy, or the use of a texaphyrin for 
internal and for external ionizing radiation. New water 
soluble hydroxy-substituted texaphyrins are described. 
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Research leading to the present invention was supported 
in part by the National Science Foundation (PYI 1986 and 
CHE 9122161) and the National Institute of Health (AI 
28845). The U.S. government therefore has certain rights in 
the invention. 
This application is a continuation-in-part application of 
then U.S. Ser. No. 08/075,123, filed Jun. 9, 1993, now 
abandoned. U.S. Ser. No. 08/075,123 is a continuation-in 
part application of then copending U.S. Ser. No. 07/822,964 
filed Jan. 21, 1992, since issued as U.S. Pat. No. 5,252,720, 
Oct. 12, 1993. U.S. Ser. No. 07/822,964 was a continuation 
in-part application of 07/771,393, now abandoned, which 
was a continuation-in-part of Ser. No. 07/539,975, since 
issued as U.S. Pat. No. 5,162,509 on Nov. 10, 1992 and a 
U.S. Ser. No. 07/539,975 was a divisional application of 
U.S. Ser. No. 07/320,293, since issued as U.S. Pat. No. 
4,935,498, Jun. 19, 1990. The entire contents of the above 
named patents and patent applications are incorporated by 
reference herein. 
FIELD OF THE INVENTION 
The present invention relates to the field of radiosensitiz 
ers and the use of texaphyrin metal complexes for radiosen 
sitization. 
BACKGROUND OF THE INVENTION 
A radiosensitizer is an agent used to enhance the effect of 
radiation therapy. Radiation therapy relies of two types of 
ionizing radiation: (1) subatomic particle radiation, which 
consists of alpha particles, beta particles (electrons), neu 
trons, protons, mesons, and heavy ions, and (2) electromag 
netic radiation, which exists as a family of waves of varying 
frequency, including high-frequency x-rays. Electromag 
netic radiation in the form of x-rays is most commonly used 
in megavoltage radiation therapy to treat common malignant 
tumors. Gamma rays, a form of electromagnetic radiation 
similar to x-rays but emitted by radioactive isotopes of 
radium, cobalt, and other elements, are also commonly used. 
Subatomic particle radiation and electromagnetic radia 
tion transfer energy to tissues as discrete packets of energy, 
called photons, that damage both malignant and normal 
tissues by producing ionization within cells. The target for 
these ions most commonly is the intranuclear DNA. 
The damaging effects of radiation therapy are mediated by 
the radiation products of water: 
The hydroxyl radical, HO, is an oxidizing radical and is 
primarily responsible for radiation damage. The radical is 
extremely reactive and short lived. It causes damage prima 
rily in the vicinity in which it is generated and if it comes in 
contact with a solvated electron (e), it will be neutralized. 
The Hradical is a reducing radical produced in low yield 
and reacts to a small extent but in a non-useful way. It, 
therefore, is not significant in the mechanism of radiation 
damage. 
Solvated electrons, e are strong reducing radicals and 
highly energetic particles. They are very small by compari 
son to the hydroxyl radical and travel great distances 
quickly. They will neutralize hydroxyl radicals readily. 














'soak up' solvated electrons and prevent them from neu 
tralizing hydroxyl radicals, thereby, allowing hydroxyl radi 
cals to do their damage. 
Most of the existing anticancer drugs act at the DNA 
level, either by direct chemical interaction, as do alkylating 
agents, or by interference with DNA biosynthesis, as in the 
case of antimetabolites (Daoud, S.S. et al., 1991). The major 
limitation with these drugs is their lack of selectivity, since 
the structure and biosynthesis of DNA in normal cells is only 
marginally different from that in tumor cells (Tritton, T. R. 
et al., 1985). As a result, most of the existing antineoplastic 
reagents have undesirable toxic effects on rapidly dividing 
normal cells. To some degree, the specificity for hypoxic 
cells can be improved by proper selection of sidechains. 
Several classes of reagents have been programmed to attack 
cellular DNA, including reagents which intercalate between 
base pairs in the duplex and those which bind to the 
phosphate layer by electrostatic association. 
The development of reagents that act against cellular loci 
other than DNA may lead to drugs that provide effective 
antitumor treatment and which are less toxic than currently 
available radiation sensitizers. One of these cellular loci is 
the cell membrane (Kale, R. K. et al., 1990). Some degree 
of drug specificity at this site seems possible because 
numerous subtle differences in composition, structure, orga 
nization, dynamics, and function exist between the surfaces 
of normal and hypoxic cells which may be exploited to 
design selective reagents. Thus, drugs which severely per 
turb membrane function or cause lipid peroxidation repre 
sent an important class of reagents. These systems are based 
on the formation of peroxyl radicals under in situ radiolysis 
in the presence of low concentrations of oxygen. 
The biological responses to radiation-induced cell injury 
are modulated by various endogenous and exogenous radio 
protectors (Painter, R. B., Radiation Biology in Cancer 
Research, pp. 59-68, 1980). Sulfhydryl compounds, includ 
ing cysteine, cysteamine, and dithiothreitol, have been 
shown to protect living cells against the lethal effects of 
ionizing radiation. It has also been observed that depletion 
of cellular sulfhydryl compounds can result in radiosensiti 
zation (Biaglow, J. E. et al., 1983). Two main mechanisms 
may be inferred for the action of sulfhydryl substrates. One 
involves scavenging of water radiolysis products, notably 
hydroxyl radicals. Evidence has also accumulated to show 
that sulfhydryl compounds can repair radiation-induced 
damage to DNA by hydrogen atom donation to transient 
oxidized species (Cadet, J. et al., 1988). Thus, an important 
feature of drug design revolves around attempting to block 
the repair mechanism. 
Cells may circumvent the lethal effects of toxins by 
altering the levels of proteins involved in their metabolic 
activation. Reduction in the levels of enzymes required for 
conversion of some reagents into their toxic metabolites has 
been shown to be an effective mode of drug resistance, 
particularly when the parent compound is relatively non 
toxic (Townsend, A.J. et al., 1989). Enzymes may also play 
a key role in resistance by enabling cells to convert toxins 
into less active or more easily removed chemical species. 
Although some of these detoxification pathways have been 
well characterized for many environmental and industrial 
toxins, their role in cellular resistance to antineoplastic drugs 
has only recently been appreciated. Among the strikingly 
diverse set of enzymes found in mammalian cells, glu 
tathione S-transferases seem to be especially effective for 
removing anticancer drugs from the system (Townsend, A. 
J. et al., 1989). Depletion of this enzyme could have a 
significant effect on the performance of certain drugs. 
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It is now recognized that cytotoxicity may result from 
minor changes in cellular levels of calcium or protons and 
from inhibition of gene expression. Such processes, if com 
bined with selective uptake of reagent into infected cells, 
offer great potential for radiotherapy because they require 
minimal generation of the active agent. This is in contrast to 
lipid peroxidation which has to be widespread before effec 
tive necrosis is observed. 
Hypoxic cells in solid tumors are relatively resistant to 
cell killing by radiation as well as by conventional chemo 
therapeutic drugs (Grau, C. et al., 1992). Although various 
types of electron-affinic reagents are known to promote 
radiosensitization of cells with diminished oxygen supply, 
relatively few show activity at nontoxic doses with in vivo 
models. Clinical trials with one of the better known reagents, 
misoimidazole, have revealed some therapeutic gain but the 
compound cannot be used at optimal dose due to neurotox 
icity (Pan, S. -S. et al., 1990). Approaches aimed at improv 
ing the therapeutic performance of nitroimidazoles have 
included lowering the lipophilicity so as to restrict nervous 
tissue penetration and accelerate renal clearance and modi 
fying the electron affinity. The objective has been to promote 
in situ formation of a stable TC-radical anion that can react 
with cellular oxygen to form superoxide ions. 
Hypoxia in solid tumors is known to result in a decreased 
effectiveness of ionizing radiation and hypoxic cells distant 
from blood vessels may also be resistant to drug-based 
therapy because of insufficient drug delivery, reduced drug 
activation under hypoxic and/or acidic conditions, or low 
activity against non-cycling hypoxic cells. On the other 
hand, certain drugs may be selectively toxic to hypoxic cells 
and might to used to improve treatment in radiotherapy. 
Information about the specific effects of reagents on well 
oxygenated and hypoxic cells is necessary for the develop 
ment of rational chemotherapeutic regimens designed to 
attack each of the physiological tumor subpopulations. Thus, 
extensive in vitro testing of new reagents must be made 
under both aerobic and hypoxic conditions and promising 
reagents must be tested against established standards. The 
most common standards are cyclophosphamide, 5-fluorou 
racil, and misoimidazole. It has been reported (Grau, C. et 
al., 1988) that whereas 5-fluorouracil is more effective 
against well oxygenated cells, misoimidazole and cyclo 
phosphamide are toxic towards both oxic and hypoxic cells 
under radiolysis. 
The present invention provides new compounds for radi 
osensitization. Texaphyrins enhance radiation damage and 
the enhancement is unaffected by the present of oxygen. 
Texaphyrins and water soluble texaphyrins have been 
described in U.S. Pat. Nos. 4,935,498 and 5,162,509 and US 
applications Ser. Nos. 07/822,964, now U.S. Pat. No. 5,252, 
720 and 08/075,123, now abandoned, all of which are 
incorporated by reference herein. 
LIST OF ABBREVIATIONS 
EDC: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
Gy Gray: a unit of absorbed radiation dose equal to 100 
radis 
Txp (txph) (tx): Texaphyrin 
SUMMARY OF THE INVENTION 
The present invention provides a method of radiation 
therapy for a host harboring a tumor. The method includes 
the steps of administering to the host a water soluble 














administering ionizing radiation to the host in proximity to 
the tumor. The texaphyrin exhibits greater biolocalization in 
the tumor relative to non-tumor tissue and has radiosensiti 
zation properties. A tumor may be a benign or malignant 
tumor or may be atheroma. A texaphyrin is an aromatic 
pentadentate expanded porphyrin analog and a texaphyrin 
having radiosensitization properties enhances cytotoxicity 
from ionizing radiation as compared to control experiments 
without the texaphyrin. Ionizing radiation includes but is not 
limited to x-rays, and internal and external gamma emitting 
radioisotopes. 
A method of treating a host harboring a tumor comprising 
the steps of i) administering to the host a water soluble 
hydroxy-substituted texaphyrin retaining lipophilicity, ii) 
determining localization sites in the host by monitoring 
texaphyrin concentrations, and iii) administering ionizing 
radiation to the host in proximity to the tumor, is a further 
aspect of the present invention. Monitoring texaphyrin con 
centrations means measuring fluorescence of an adminis 
tered free base texaphyrin or by reference to the metal of an 
administered texaphyrin metal complex. If the metal is 
paramagnetic, then magnetic resonance imaging is used for 
measurement, if the metal is a gamma emitting radioactive 
metal, then Yemission is used for measurement. 
In each of these methods, the water soluble hydroxy 
substituted texaphyrin may be complexed with a metal, 
although the metal is not central to the radiosensitization 
properties of the texaphyrins. The metal is important to the 
stability of the texaphyrin complex. 
A further embodiment of the present invention is a 
method of treating a host harboring a tumor comprising the 
steps of i) administering to the host as a first agent a water 
soluble hydroxy-substituted texaphyrin retaining lipophilic 
ity, ii) determining localization sites in the host by moni 
toring texaphyrin concentrations, iii) administering to the 
host as a second agent a water soluble hydroxy-substituted 
texaphyrin-diamagnetic metal complex retaining lipophilic 
ity, and iv) administering ionizing radiation and photoirra 
diation in proximity to the tumor. The second agent has 
essentially identical biolocalization property and may 
exhibit the ability to generate singlet oxygen upon exposure 
to light. The photodynamic effect may be derived from 
anaerobic electron transfer processes. A preferred diamag 
netic metal texaphyrin complex is the Lu(III), La(III) or 
In(III) complex of B2T2. 
In these methods, determining localization sites may 
occur by observing fluorescence from the texaphyrin, in 
particular, a free base ring N-derivatized texaphyrin. When 
the first agent is complexed with a metal, the metal may be 
a gamma-emitting metal and determining localization sites 
would occur by gamma body imaging, or the metal may be 
a paramagnetic metal and determining localization sites 
would occur by magnetic resonance imaging. The ionizing 
radiation may be from an external source or the metal may 
be a radioactive metal. In that case, the ionizing radiation is 
from the radioactive metal in combination with radiation 
from an external source. Exhibiting greater biolocalization 
in the tumor relative to non-tumor tissue means having an 
inherently greater affinity for tumor tissue relative to non 
tumor tissue. Essentially identical biolocalization property 
means the second agent is a texaphyrin derivative having 
about the same selective targeting characteristics in tissue as 
demonstrated by the first agent. The first agent and the 
second agent may be the same texaphyrin. 
The texaphyrin may have the structure: 
5,457,183 
R, R2, R, R, R and R are independently hydrogen, 
hydroxyl, alkyl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, 
saccharide, carboxyalkyl, carboxyamidealkyl, biomolecule 
or a couple to a biomolecule. At least one of R,R,R,R, 
Rs and R is oxyhydroxyalkyl, saccharide, oxyalkyl, car 
boxyalkyl, carboxyanidealkyl, hydroxyalkyl, biomolecule 
or a couple to a biomolecule having at least one hydroxy 
substituent. R is alkyl. In a preferred embodiment, R is 
methyl. 
The texaphyrin may have the structure: 
Nt 
R5 
M may be H, a divalent metal cation selected from the 
group consisting of Ca', Mn', Co', Ni', Zn', 
Cd', Hg, Fe", Sm' and UO,' or a trivalent metal 
cation selected from the group consisting of Mn", 
Co", Nit3, Fe", Hot, Ce", Y+3, Int, Pr'3, Nd'3, 
Sm', Eu", Gd, Tb'3, Dy", Er", Tm", Yb'-3, Lu 
3, La", and U. R. and Ra are CHCH, R is CH, 
R, R and Rs are independently hydrogen, hydroxyl, 
alkyl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, sac 
charide, carboxyalkyl, carboxyamidealkyl, biomol 
ecule or a couple to a biomolecule where at least one of 
R., R., and R is oxyhydroxyalkyl, saccharide, oxy 
alkyl, carboxyalkyl, carboxyamidealkyl, hydroxyalkyl, 
biomolecule or a couple to a biomolecule having at 
least one hydroxy substituent. Nis 0, 1 or 2. 
The oxyhydroxyalkyl may be Co-Ho-1-2O,O, or 
OCH22O,O, where n is a positive integer from 
1 to 10, x is zero or a positive integer less than or equal to 
n, and y is Zero or a positive integer less than or equal to 
((2n+1)-2x). The oxyhydroxyalkyl or saccharide may be 
C.Ho-1 OR OC, Ho-1-O Ra or 














is Zero or a positive integer less than ((2n+1)-q), q is Zero 
or a positive integer less than or equal to 2n+1, R is 
independently H, alkyl, hydroxyalkyl, saccharide, Co 
w)Hon-1)-2O.O. O2CCon-Hicon-O.O. O 
N(R)OCCH22O, O, M is a positive integer 
from 1 to 10, w is zero or apositive integer less than or equal 
to m, Z is zero or a positive integer less than or equal to 
((2m+1)-2w). R is H, alkyl, hydroxyalkyl, or CH2 
rO.R, where m is a positive integer from 1 to 10, zis zero 
or a positive integer less than ((2m+1)-r), r is zero or a 
positive integer less than or equal to 2m+1, and R is 
independently H, alkyl, hydroxyalkyl, or saccharide. 
The carboxyamidealkyl is (CH),CONHR", 
O(CH,)CONHR, (CH),CON(R), O 
O(CH2)CONCR) where n is a positive integer from 1 to 
10, and R is independently H, alkyl, hydroxyalkyl, saccha 
ride, Con-whic(2n+1 -2.O.O. O2CCon-whom 1. -2OO 
z or NCR) OCCH-20, O M is a positive inte 
ger from 1 to 10, w is zero or a positive integer less than or 
equal to m, Z is Zero or a positive integer less than or equal 
to ((2m+1)-2w), and R is H, alkyl, hydroxyalkyl, or 
C.H.O.R. M is a positive integer from 1 to 10, Z 
is zero or a positive integer less than ((2m+1)-r), r is zero 
or a positive integer less than or equal to 2m+1, and R is 
independently H, alkyl, hydroxyalkyl, or saccharide. 
The carboxyalkyl is CH2O,R or OCH2-1- 
aOR where n is a positive integer from 1 to 10, y is zero 
or a positive integer less than ((2n+1)-q), q is zero or a 
positive integer less than or equal to 2n+1, and R is 
(CH2)CO2R, (CH),CONHR or (CH2)CONCR), N is a 
positive integer from 1 to 10, R is independently H, alkyl, 
hydroxyalkyl, Saccharide, CH21- 20 O, 
O2CCon Hon 1-2O, O, or N(R) OCCon-Ho-1- 
2w)OO, where m is a less than or equal to m, Z is zero or 
a positive integer less than or equal to ((2m+1)-2w), R is H, 
alkyl, hydroxyalkyl, or CH2--OR, M is a positive 
integer from 1 to 10, Z is zero or a positive integer less than 
((2m+1)-r), ris Zero or a positive integer less than or equal 
to 2m+1, and R is independently H, alkyl, hydroxyalkyl, or 
saccharide. The biomolecule may be an oligonucleotide, an 
antibody, a peptide having affinity for a biological receptor, 
or a sapphyrin molecule. A preferred texaphyrin is B2T2 and 
a preferred paramagnetic metal is Gd(III), Mn(II), Mn(III), 
Fe(III) or a trivalent lanthanide other than Ln(III), Lu(III) 
and Pm(III). 
A preferred embodiment of the present invention is a 
method of radiation therapy for a host harboring a tumor 
comprising the steps of i) administering to the host a 
pharmaceutically effective amount of the Gd complex of 
B2T2,4,5-diethyl-10,23 -dimethyl-9,24-bis(3-hydroxypro 
pyl)-16,17- (3-hydroxypropyloxy)-13,20,25,26,27-pen 
taazapentacyclo (20.2.1.1.1.0', heptacosa-1,3,5,7, 
9,11(27),12,14(19), 15,1720,22(25),23-tridecaene; and ii) 
administering ionizing radiation to the host in proximity to 
the tumor. 
Texaphyrin compounds, the structures of which were just 
described, are an aspect of the present invention as new 
compositions of matter. Specific embodiments of the texa 
phyrins are where R is CHCHCONCHCCHOH) and Rs 
and R are OCH, OCHCHCH-OH; OCHCH-OH: 
O(CH2CH2)CHCHOR", where n is an integer less than 
or equal to 10 and R is Hor CH; independently H or CH; 
or Rs is CH, and R is H, CH, OCH, OCHCH-OH, 
OCHCH, CHOH, or O(CHCHO)CHCHOR', where n 
is an integer less than or equal to 10 and R is H or CH. R. 






CHCHCOOC6HOs, and Rs and Rare as just described. 
Texaphyrins having different R groups on the B portion of 
the molecule, an R group on a ring nitrogen, or 4 or more 
hydroxyl groups on the tripyrrole portion of the molecule 
could all be useful for radiosensitization as well as imaging 
and localization. The hydroxylated texaphyrin B2T2 is a 
preferred texaphyrin for these methods, however, the poten 
tial of these further derivatives is further localization speci 
ficity that may be introduced by various substituents on the 
molecule. Any texaphyrin that binds to tumors whether 
hydroxylated or not may be used for radiosensitization. 
A further embodiment of the present invention is a 
method for synthesizing an aromatic pentadentate expanded 
porphyrin analog having an alkyl group on a central tripyr 
rane ring nitrogen. The method comprises the steps of i) 
mixing, in an organic solvent, a nonaromatic pentadentate 
expanded porphyrin analog having an alkyl group on a 
central tripyrrane ring nitrogen, a Bronsted base and an 
oxidant; and ii) stirring at ambient temperature or heating 
the mixture at reflux for at least two hours. The nonaromatic 
pentadentate expanded porphyrin analog having an alkyl 
group on a central tripyrrane ring nitrogen is produced by 
condensation of a diformyltripyrrole having structure A, and 
an orthophenylenediamine having structure B: 
R4 R R3 R2 R1 R4 A 
Rg N N N R8 
H R7 H 
H2N. R5 B 
H2N Ré. 
R,R,R,R,Rs and R are independently H, OH, alkyl, 
oxyalkyl, hydroxyalkyl, oxyhydroxyalkyl, saccharide, 
carboxyalkyl, carboxyamidealkyl, biomolecule or a 
couple to a biomolecule; R is alkyl; R is aldehyde, 
carboxylic acid or derivative thereof, and the molecular 
weight of any one of R, R2, Ra, Ra, or R5 is less than 
or equal to about 1000 daltons. In a preferred embodi 
ment, R, is methyl, the Bronsted base is triethylamine, 
and the oxidant may be air saturating the organic 
solvent, oxygen, platinum oxide or 2,3-dichloro-5,6- 
dicyano-1,4-benzoquinone. The stirring or heating at 
reflux step comprises stirring or heating at reflux the 
mixture for at least 24 hours. 
The organic solvent may comprise methanol and chloro 
form, methanol and benzene, or methanol and dimethylfor 
mamide. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a schematic representation of the reduced 
(1) and oxidized (1) forms of the free-base "texaphyrin' 
and a representative five coordinate cadmium complex (1) 
derived from this "expanded porphyrin'. 
FIG. 2 schematically summarizes the synthesis of texa 
phyrin (2 also designated 1 in FIG. 1). 
FIG. 3 shows H NMR spectrum of 1.NO in CDCla. 
The signals at 1.5 and 7.26 ppm represent residual water and 
solvent peaks respectively. 
FIG. 4 shows a UV-visible spectrum of 1.NO 1.50x10 














FIG. 5 shows metal complexes and derivatives (5A-5) of 
texaphyrin macrocycles. 
FIG. 6 schematically summarizes the synthesis of B2TXP, 
6 and LuB2TXP'', 6. 
FIG. 7 schematically summarize the synthesis of 
B2T2TXP(7) and lanthanide metal complexes of B2T2, 
7-7. 
FIG. 8 schematically summarizes the synthesis of 
B4T2TXP(8) and (Gd B4T2 TXP*(8). 
FIG.9 shows the synthesis of texaphyrin metal complexes 
with different R groups on the B portion of the molecule. 
FIGS. 10A, 10B and 10C show covalent coupling of 
texaphyrin metal complexes with amine-, thiol- or hydroxy 
linked oligonucleotides (10A), the synthesis of aminosac 
charidetexaphyrin conjugates by ester-to-amide exchange 
(10B), and the synthesis of aminosaccharide-texaphyrin and 
oligopeptide texaphyrin conjugates by carbodiimide medi 
ated reaction with carboxy-substituted. texaphyrins (10C). 
FIG. 11 summarizes the synthesis of polyether-linked 
polyhydroxylated texaphyrins. Ts is a tosyl group. 
FIG. 12 Summarizes the synthesis of catechol (i.e. ben 
Zene diol) texaphyrin derivatives bearing further hydroxy 
alkyl substituents off the tripyrrane-derived portion of the 
macrocycle. 
FIG. 13 provides an example of a saccharide substituted 
texaphyrin in which the saccharide is appended via an 
acetal-like glycosidic linkage. Triflate is trifluoromethane 
Sulfonate. 
FIG. 14 summarizes the synthesis of a doubly carboxy 
lated texaphyrin system in which the carboxyl groups are 
linked to the texaphyrin core via aryl ethers or functional 
ized alkyl substituents. The products of this scheme, com 
pounds 14 and 14 could be converted on to various 
esterified products wherein the ester linkages serve to 
append further hydroxyl-containing substituents 
FIG. 15 summarizes the synthesis of polyhydroxylated 
texaphyrin derivatives via the use of secondary amide link 
ages. DCC is dicyclohexylcarbodiimide, DMF is dimethyl 
formamide, and DME is dimethoxyethane. 
FIG. 16 summarizes the synthesis of another set of 
polyhydroxyl substituted texaphyrin derivatives using simi 
lar amide bonds as in FIG. 15. 
FIG. 17 summarizes the synthesis of saccharide substi 
tuted texaphyrins, wherein the saccharide moieties are 
appended via amide bonds. 
FIG. 18 summarizes the synthesis of polyhydroxylated 
texaphyrin derivatives containing branched polyhydroxyl 
(polyol) subunits appended to the texaphyrin core via aryl 
ethers. 
FIG. 19 summarizes how similar polyol subunits may be 
appended via ester linkages. 
FIG. 20 shows the synthesis of a derivative of texaphyrin 
having an R group on a ring nitrogen 20. 
FIG. 21 summarizes the synthesis of a T4 tripyrrane 
dialdehyde using two different methods. Precursor 21A is 
derivatized with serinol in the presence of 1,1'-carbonyldi 
imidazole to form 21; Precursor 21A is derivatized with 
diethanolamine to form 21. 
FIG. 22 summarizes the synthesis of a T8 tripyrrane 
dialdehyde. Precursor 21 is derivatized with D-glu 
cosamine.HCl in the presence of 1,1'-carbonyldiimidazole to 
form 22. 
FIG. 23 summarizes the synthesis of a T10 tripyrrane 
dialdehyde. Precursor 21 is derivatized with N-methylglu 
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camine in the presence of 1,1'-carbonyldiimidazole to form 
23B. 
FIG. 24 shows diamines for reacting with tripyrrane 
dialdehydes to form sp. macrocycles. 
24 is 4,5-dimethoxy-1,2-phenylenediamine, 
24 is 4,5-dimethyl-1,2-phenylenediamine, 
24c is 1,2-diamino-4,5-bis((3'-hydroxyethyl)oxy)ben 
Zene, 
24 is 1,2-diamino-4,5-bis((3'-hydroxypropyl)oxy)ben 
Zene, 
24 is the 4,5-bis(polyethylene glycol monomethyl ether) 
substituted derivative of 1,2-o-phenylenediamine, and 
24 is the 4,5-bis(polyethylene glycol) substituted deriva 
tive of 1,2-o-phenylenediamine. 
In 24 24, n is an integer less than or equal to 10. 
FIGS. 25A and 25B summarize the synthesis of T4 
macrocycles. 
FIGS. 26A and 26B summarize the synthesis of T2, T4 
and T6 macrocycles. 
FIGS. 27A and 27B summarize the synthesis of T8-T10 
macrocycles. 
FIGS. 28A and 28B summarize the synthesis of T8-T12 
macrocycles. 
FIGS. 29A and 29B summarize the synthesis of T8-T10 
macrocycles. 
FIGS. 30A and 30B summarize the synthesis of T8-T12 
macrocycles. 
FIG. 31 shows pulse radiolysis in aqueous isopropanol. 
The optical density is plotted versus time in useconds for the 
formation of the gadolinium texaphyrin anion, GdTX. 
Only reducing radicals are present in isopropyl alcohol since 
the proton removed from isopropyl alcohol combines with 
the oxidizing radical HO to form water. 
FIGS. 32A and 32B show the decay of the anion formed 
in FIG. 31 versus time in mseconds. The plot in 32A 
demonstrates that the anion has a long half life which is not 
affected by the presence of oxygen as shown in 32B. These 
data indicate that the TXP anion has a lower reduction 
potential than oxygen and therefore does not pass its elec 
trons to oxygen. 
FIG. 33 shows the rate constants for the covalent modi 
fication of cytosine by the texaphyrin radical, GdTx(H). 
These data indicate that the texaphyrin radical, while rela 
tively stable, is nevertheless reactive and will cause damage 
to neighboring molecules. 
FIG. 34 shows the killing of mouse L1210 cells versus 
dose of radiation (in Grays) in the presence and absence of 
20 uM GdTXP. The sensitizer enhancement ratio is 1.62. 
FIG. 35 shows the effect of GdTXP on L1210 cell kill. 
Sensitizer enhancement ratios are plotted versus concentra 
tion of GdTXP. An SER greater than 1.5 is clinically 
significant. These data indicate that the effectiveness of 
GdTXP as a sensitizer increases with the concentration 
achieved. 
FIG. 36 shows the effect of GdTXP on nucleic acid strand 
scission under radiolysis at 25 grays. L1210 cells were 
exposed to GdTXP at the indicated concentrations, lysed and 
the nucleic acid material passed through a size selection 
filter. 
FIGS. 37A, 37B and 37C show axial MRI scans of rabbit 
thigh muscle bearing a transplanted V2 carcinoma before 
(37A), 30 minutes (37B) and 3 hours (37C) after the 
administration of 5 umol GdTXP (acetate) per kg body 
weight. The pulsing sequences used were conventional spin 
echo sequences TR/TE-300/15, 16 Khz., 3 mm slice thick 
ness and 256x192 matrix, 2 NEX, saturation inferiorly and 















DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The present invention involves the use of texaphyrins, in 
particular, hydroxy-substituted texaphyrins for localization, 
radiosensitization, radiation therapy and photodynamic 
tumor therapy. More particularly, the invention demon 
strates enhanced cytotoxicity from radiation and enhanced 
nucleic acid strand scission in the presence of a gadolinium 
texaphyrin complex. Examples 1-9 describe the synthesis of 
texaphyrins. Examples 10-14 describe the use of texaphy 
rins for imaging, radiosensitization, radiation therapy and 
photodynamic tumor therapy. 
The introduction of hydroxy substituents on the B (ben 
Zene ring) portion of the texaphyrin molecule is accom 
plished by their attachment to phenylenediamine in the 4 and 
5 positions of the molecule. The introduction of hydroxy 
substituents on the T (tripyrrole) portion of the molecule is 
accomplished by appropriate functionalization of the alkyl 
substituents in the 3 and/or 4 positions of the pyrrole rings 
at a synthetic step prior to condensation with the substituted 
phenylenediamine. Standard deprotection methodology 
such as ester hydrolysis may be used to unmask the free 
hydroxyl substituents. These derivatives exhibit significant 
solubility in aqueous media, up to 1 mM or better, yet they 
retain affinity for lipid rich regions which allows them to be 
useful in biological environments. 
Divalent and trivalent metal complexes of texaphyrins are 
by convention shown with a formal charge of N, where 
N=1 or 2, respectively. It is understood by those skilled in 
the art that the complexes described in the present invention 
may have one or more additional ligands providing charge 
neutralization and/or coordinative saturation to the metal 
ion. Such ligands include chloride, nitrate, acetate, and 
hydroxide, among others. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. Although any methods and materials 
similar or equivalent to those described herein can be used 
in the practice or testing of the present invention, the 
preferred methods and materials are now described. Unless 
mentioned otherwise, the techniques employed herein are 
standard methodologies well known to one of ordinary skill 
in the art. 
EXAMPLE 1. 
Synthesis of Compounds 1-1 
This example describes the synthesis of compounds 
depicted in FIGS. 1 and 2; the nonaromatic methylene 
bridged macrocycle 1A, the expanded porphyrin named 
“texaphyrin' 1 and the nitrate salt of the cadmium (II) 
complex 1. 
All solvents and reagents were of reagent grade quality, 
purchased commercially, and used without further purifica 
tion. Sigma lipophilic Sephadex (LH-20-100) and Merck 
type 60 (230–400 mesh) silica gel were used for column 
chromatography. Melting points were recorded on a Mel 
temp Laboratory Devices capillary apparatus and are uncor 
rected. 
2.5-Bis(5-(benzyloxycarbonyl)-3-ethyl-4-methylpyrrol 
2-yl)methyl)-3,4-diethylpyrrole (2, FIG. 2) .. 3,4-Dieth 
ylpyrrole (2, FIG. 2) (0.6 g., 4.9 mmol), benzyl 5-(ac 
etoxymethyl)-3-methyl-4-ethyl-pyrrole-2-carboxylate (2, 
FIG. 2) (2.5g, 7.9 mmol), and p-toluenesulfonic acid (0.15 
g) were dissolved in 60 mL of absolute ethanol and heated 
5,457,183 
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at 60° C. for 8 h under nitrogen. The resulting suspension 
was reduced in volume to 30 mL and placed in the freezer 
for several hours. The product was then collected by filtra 
tion, washed with a small amount of cold ethanol, and 
recrystallized from dichloromethane-ethanol to afford a 
white powder (2.07 g., 82%); mp 21.1° C. NMR spectra and 
high resolution mass spectral data were obtained as 
described. 
2,5-Bis(3-ethyl-5-formyl-4-methylpyrrol-2-yl)methyl)- 
3,4-diethylpyrrole (2 FIG. 2). The above diester (2) (4.5 
g, 7.1 mmol) was dissolved in 500 mL of dry THF contain 
ing 1 drop of triethylamine and hydrogenated over 5% 
palladium-charcoal (250mg) at 1 atm H. pressure until the 
reaction was deemed complete by TLC. The catalyst was 
separated and the solution was taken to dryness on the rotary 
evaporator. Recrystallization from dichloromethane-hexane 
yielded 2 (3.2g, quantitative) as a white powder which 
quickly develops a red hue upon standing in air: mp 
1119-115° C. dec. The above diacid (3 g, 6.6 mmol) was 
dissolved in 5 mL of freshly distilled trifuoroacetic acid and 
heated at reflux for 5 min under nitrogen and allowed to cool 
to room temperature over the course of 10 min. The above 
heating and cooling sequence was repeated once more and 
the resulting dark oil was then cooled in an ice-salt bath. 
Freshly distilled triethylorthoformate (5 mL) was then added 
dropwise with efficient stirring. After 10 min the solution 
was poured into 300 mL of ice water and let stand 30 min. 
The dark red precipitate was collected by filtration and 
washed well with water. Ethanol (ca. 50 mL) was then used 
to wash the precipitate from the filter funnel into 350 mL of 
10% aqueous ammonia. The resulting yellow suspension 
was stirred well for an hour and then extracted with dichlo 
romethane (5x150 mL). The dichloromethane extracts were 
washed with water, dried over MgSO, and evaporated to 
dryness on the rotary evaporator to give 2, as an off-white 
mass. Two recrystallizations from chloroform-ethanol gave 
crystalline product (1.91 g, 68%) with mp 202-203° C. 
NMR spectra and high resolution mass spectra data were 
obtained as described and are reported. 
4.5,9.24 -Tetraethyl-10,23-dimethyl-13,20,25,26,27-pen 
taazapentacyclo(20.2.1.1.1.0'']heptacosa-3,5,8,10, 
12,14-(19),15, 17,2022,24-undecaene (1). A. Acid-Cata 
lyzed Procedure. The diformyltripyrrane (2, FIG. 2) (105 
mg, 0.25 mmol) and o-phenylenediamine (27 mg., 0.25 
mmol) were dissolved, with heating, in a degassed mixture 
of 300 mL of dry benzene and 50 mL of absolute methanol. 
Concentrated HCl (0.05 mL) was then added and the result 
ing gold solution heated at reflux for 24 h under nitrogen. 
After cooling, solid K2CO (20 mg) was added and the 
solution filtered through MgSO4. The solvent was then 
removed on the rotary evaporator and the resulting product 
dissolved in 50 mL of CH2Cland refiltered (to remove 
unreacted 2). Heptane (100 mL) was added to the filtrate 
and the volume reduced to 50 mL on the rotary evaporator 
whereupon the flask was capped and placed in the freezer 
overnight. The resulting white powder was then collected by 
filtration, washed with hexane, and dried in vacuo to yield 1 
(55 mg, 44%); mp 1889-190° C. 
Metal Template Procedure. The diformyltripyrrane 2 and 
o-phenylenediamine reactants were condensed together on a 
0.25-mmol scale exactly as described above except that 1.0 
equiv of either Pb(SCN) (80 mg) or UOC (85 mg) was 
added to the boiling solution at the outset of the reaction. 
Following workup as outlined above, 68 mg (69%) and 60 
mg (61%) of 1 were obtained respectively for the Pb'- and 
UO'-catalyzed reactions. The products produced in this 














NMR spectra and high resolution mass spectra data were 
obtained as described. 
4,5,9,24-Tetraethyl-10,23-dimethyl-13,20,25,26,27-pen 
taazapentacyclo[20.2.1.1.1'. O'' heptacosa-1,3,5,7, 
9,11(27), 12, 14,16,18,20,22 (25),23-tridecaene, free-base 
"texaphyrin' 1. Macrocycle 1 (50 mg, 0.1 mmol) was 
stirred in methanol/chloroform (150 ml, w/v/2/1) in the 
presence of N, N,N',N'-tetramethyl-1,8-diaminonaphtha 
lene ("proton sponge') for one day atroom temperature. The 
reaction mixture was then poured into ice water. The organic 
layer was separated and washed with aqueous ammonium 
chloride solution and then brine (a saturated solution of 
sodium chloride in water). Following concentration on a 
rotary evaporator, the crude material was purified by chro 
matography on SEPHADEX using first pure chloroform and 
then chloroform/methanol (v/v/10/1) as eluents. After sev 
eral faster red bands were discarded, a dark green band was 
collected, concentrated in vacuo, and recrystallized from 
chloroform/n-hexane to give the sp’ form of the ligand as a 
dark green powder in yields ranging from 3-12% with the 
better yields only being obtained on rare occasions. Spectral 
data are reported in patent application SN 07/771,393. 
The preparation of complex 1. NO was as follows: the 
reduced spform of the macrocyclic compound (1A) (40 mg, 
0.08 mmol) was stirred with cadmium nitrate tetrahydrate 
(31 mg, 0.1 mmol) in chloroform/methanol (150 ml, w/vl 
1/2) for 1 day. The dark green reaction mixture was then 
concentrated and purified by chromatography on silica gel as 
described above. The resulting crude material was then 
recrystallized from chloroform/n-hexane to give analytically 
pure 1. NO in 27% yield. Under the reaction conditions 
both ligand oxidation and metal complexation take place 
spontaneously. Spectral data are reported in patent applica 
tion SN 07/771,393. 
EXAMPLE 2 
Synthesis of compounds 5-5. 
All solvents and reagents were of reagent grade quality, 
purchased commercially, and used without further purifica 
tion. Sigma lipophilic SEPHADEX (LH-20-100) and Merck 
type 60 (230–400 mesh) silica gel were used for column 
chromatography. 
Compound 5 is the metal adduct of ligand 5A which was 
obtained in ca. 90% yield by condensing 1,2-diamino-4,5- 
dimethylbenzene with 2,5-Bis-(3-ethyl-5-formyl-4-meth 
ylpyrrol-2 -ylmethyl)-3,4-diethylpyrrole under acid cata 
lyzed conditions identical to those used to prepare 1. The 
sp' form of ligand 5A (42 mg, 0.08 mmol) was stirred with 
gadolinium acetate tetrahydrate (122 mg, 0.3 mmol) and 
Proton SpongeTM, N, N, N, N'-tetramethyl-1,8-diaminon 
aphthalene (54 mg, 0.25 mmol) in chloroform/methanol 
(150 ml, w/v 1/2) for one day at room temperature. The dark 
green reaction mixture was concentrated under reduced 
pressure and chromatographed through silica gel (25 cm.X 
1.5 cm.) which was pretreated with chloroform/triethy 
lamine (50 ml, viv 25/1). Chloroform/triethylamine (25/1) 
and chloroform/methanol/triethylamine 25/2.5/1 v/v) was 
used as eluents. A dark red band was first collected followed 
by two green bands. The last green band, which showed a 
clear aromatic pattern by UV/VIS, was concentrated and 
recrystallized from chloroform/n-hexane to give 14 mg 
(22%) of the Gd complex 5. 
Treatment of compound 5 with Gd(OAc), Eu(OAc), 
and Sm(OAc) under reaction and work-up conditions simi 
lar to those used to obtain 1, then gave the cationic 
complexes 5, 5, and 5, as their dihydroxide adducts, in 
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22%, 33%, and 37% yields respectively. As judged by the IR 
and microanalytical data, under the reaction and work up 
conditions, hydroxide anions serve to displace the acetate 
ligands presumably present following the initial metal inser 
tion procedure. 
EXAMPLE 3 
Synthesis of texaphyrin derivative B2. 
H and 'C NMR spectra were obtained on a General 
Electric QE-300 (300 MHz.) spectrometer. Electronic spec 
tra were recorded on a Beckman DU-7 spectrophotometer in 
CHCl Infrared spectra were recorded, as KBrpellets, from 
4000 to 600 cm on a Nicolet 510PFT-IR spectrophotom 
eter. Chemical ionization mass spectrometric analyses (CI 
MS) were made using a Finnigan MAT 4023. Low resolu 
tion and high resolution fast atom bombardment mass spec 
trometry (FABMS) were performed with a Finnigan-MAT 
TSQ-70 and VG ZAB-2E instruments, respectively. A 
nitrobenzyl alcohol (NBA) matrix was utilized with CHCl 
as the co-solvent. Elemental analyses were performed by 
Atlantic Microlab, Inc. Melting points were measured on a 
Mel-temp apparatus and are uncorrected. 
Materials. All solvents and reagents were of reagent grade 
quality, purchased commercially, and used as received. 
Merck Type 60 (230-400 mesh) silica gel was used for 
column chromatography. Thin-layer chromatography was 
performed on commercially prepared Whatman type silica 
gel 60A plates. 
1,2-bis(2-carboxy) ethoxy)-4,5-dinitrobenzene. 6, FIG. 
6; To a well stirred solution of o-bis((3-hydroxypropyl)oxy) 
benzene (5.0g, 22 mmol) in 30 mL. glacial acetic acid cooled 
to 15° C., 20 mL of concentrated nitric acid (70%) was 
added dropwise over a period of 15 minutes. The tempera 
ture was held below 40 C. by cooling and proper regulation 
of the rate of acid addition. After the addition, the yellow 
solution was stirred at room temperature for 15 minutes. 
Here, the solution was cooled again to 15° C. and 50 mL of 
fuming nitric acid (90%) was added dropwise over a period 
of 30 minutes. The orange solution was brought to room 
temperature and stirred for approximately 48 hours. After 48 
hours, the reaction solution was checked by TLC, which 
displayed only one low Rf spot, the diacid. Therefore, the 
orange solution was poured onto 600 mL of ice in a 1 liter 
beaker. The precipitated dinitro product was filtered, washed 
with water (1000 mL) until free from acid and dried in vacuo 
for 24 hours. The crude product was recrystallized from 
acetone/n-hexanes to yield the diacid as fluffy yellow 
needles (4.20 grams, 55.2%). For the diacid: 'H NMR 
(d-acetone) 8: 2.87 (t, 4H, OCHCHCO2H), 4.49 (t, 4H, 
OCHCHCOH), 7.71 (s, 2H, Ar-H), 9-10 (bris, 2H, 
COH). C NMR (d6-acetone) 8: 33.76, 66.57, 109.85, 
137.14, 152.06, 171.51. EI MS, m/z (rel. intensity: 346 
(100)) 
1,2-bis((3-hydroxypropyl)oxy)-4,5-dinitrobenzene. 6, 
FIG. 6. In a dry 500 mL round bottom flask, equipped with 
a 125 mL pressure equalized dropping funnel, 1,2bis((2- 
carboxy) ethoxy)-4,5-dinitrobenzene (5.0 g, 14.5mmol) was 
dissolved in 50 mL dry THF (distilled over ketyl) and stirred 
at 0°-10 C. under nitrogen. To the resulting clear solution, 
120 mL of BHs. THF (1M) was added dropwise over a 
period of 30 minutes. After the borane addition, the reaction 
mixture was stirred an additional 5 minutes at 10° C. and 
then it was brought up to room temperature. The formation 
of the diol product was followed by TLC and the reaction 
was deemed complete after approximately 2 hours. The 














of absolute methanol (Careful: frothing occurs!). After stir 
ring the yellow solution for 30 minutes, it was concentrated 
to a bright yellow solid on a rotary evaporator. The crude 
solid was dissolved in 200 mL ethyl acetate and washed with 
4M sodium acetate (2x100 mL), water (2x100 mL) and then 
brine (50 mL). The organic layer was dried over MgSO and 
concentrated to dryness on a rotary evaporator. The crude 
product was recrystallized from acetone/n-hexanes to afford 
4.12 grams (90%) of orange needles. For the diol: mp 
129°-130° C.; H NMR (CDC) 8: 2.10 (p, 4. 
ocHCCHOH), 3.81 (t, 4H, OCHCHCH-OH), 4.28 (t, 
4H, OCCHCH.OH), 7.41 (s, 2H, Ar-H). 'C NMR (d. 
acetone) 8:32.52, 58.50, 67.81, 107.88, 137.03, 152.47. EI 
MS, m/z (rel, intensity): 316 (100); HRMS (M") 316.0914 
(calcd. for CHNO:316,0907). 
1,2-Diamino-4,5-bis (3'-hydroxypropyl)oxybenzene, 6, 
FIG. 6. The diamine was obtained by reduction of the 
corresponding 1,2-bis (3-hydroxypropyl) oxy) -4,5-dini 
trobenzene (3.0 g, 9.6 mmol) with hydrazine hydrate (4.7 
mL, 96.2 mmol) and 10% palladium on carbon (200 mg) in 
120 mL refluxing absolute ethanol. The resulting brown 
suspension bubbled for approximately 15-20 minutes and 
then turned colorless after 1 hour. At this point, the reduction 
was deemed complete as judged by TLC (alow R spot). The 
reaction solution was hot filtered through celite into a dry 
flask, covered with aluminum foil, and then concentrated to 
a gray solid. The diamine was recrystallized from hot 
acetone/n-hexanes to yield 2.20 grams (91%) of an off-white 
fine powder. For the diamine: mp 115°-117° C.; H NMR 
(d-DMSO) 8:1.76 (p, 4H, OCHCHCH-OH), 3.53 (q, 4H, 
OCHCHCH-OH), 3.82 (t, 4H, OCHCHCHOH), 4.06 
(s, 4H, NH), 444 (t, 2H, OH), 6.25 (s, 2H, ArH). CNMR 
(d-DMSO) 8:42.68, 67.84, 77.08, 114.95, 139.01, 150.63. 
EI MS, m/z (rel. intensity): 256 (100); HRMS (M) 256. 
1420 (calcd for CHNO: 256.1423). 
4,5,9,24-Tetraethyl-16, 17-his((3-hydroxypropyl)oxy)- 
10,23 -dimethyl- 13,20,25,26,27-pentaazapentacyclo 
(20.2.1.13. 18. O'' heptacosa-3,5,8,10,12,14(19), 
15, 17,2022,24-undecaene. sp. B2 TXP, 6, FIGS. 6. This 
macrocycle was prepared in >90% yield from 1,2-diamino 
4,5-bis((3-hydroxypropyl)oxy) benzene and 2,5-bis ((3- 
ethyl-5-formyl-4-methylpyrrol-2-yl) methyl )-3,4-diethyl 
pyrrole by using the acid-catalyzed procedure reported ear 
lier for the preparation of the reduced sp texaphyrin, see 
Example 1. For B2 sp texaphyrin: mp 190° C. dec; H 
NMR (CDC1) 8: 1.05 (t, 6H, CHCH), 1.12 (t, 6H, 
CHCH), 2.00 (t, 4H, OCHCHCH-OH), 2.28 (s, 6H, 
pyrr-CH), 2.35 (q, 4H, CHCH), 2.48 (q, 4H CH2CH3), 
3.00-3.50 (bs, 2H, OH), 3.78 (t, 4H, OCHCHCH-OH), 
3.93 (s, 4H, (pyrr) 2-CH2), 4.19 (s, 4H, OCHCHCH-OH), 
7.16 (s, 2H, ArH), 8.34 (s, 2H, CHN), 11.16 (s, 1H, NH), 
12.04 (s, 2H, NH); CNMR (CDC) 8:9.65, 15.45, 16.61, 
17.23, 17.60, 22.18, 31.71, 60.75, 68.58, 100.86, 120.23, 
120.37, 124.97, 125.06, 130.05, 133.86, 140.16, 140.86, 
147.62; UV/vis 369 mm; CIMS (M) 642; CIHRMS 
(M) 642. 4039 (calcd for CH4NO: 642.4019). Texa 
phyrin macrocycles having a free carboxyl or a free amino 
group for further derivatization on the benzene ring portion 
of the molecule can be synthesized by replacing 6 of FIG. 
6 with 3,4 diaminobenzoic acid or 3,4 diaminoaniline. Such 
macrocycles can be further functionalized to the derivatives 
shown in FIG. 23. 
Lutetium (III) complex of 4,5,9.24-tetraethyl-16, 17-bis(( 
3-hydroxypropyl)oxy)-10,23-dimethyl-13,20,25,26,27-pen 
taazapentacyclo (20.2.1.1. 1'. O']heptacosa-1,3,5,7, 
9,11 (27), 12,14(19), 15, 17.20,22(25),23-tridecaene 
LuB2Txp'6, FIG. 6. A mixture of the reduced texaphy 
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rin ligand, 45,924-16,17-bis((3-hydroxypropyl) oxy) - 
10,23 -dimethyl-13,20,25,26,27-pentaazapentacyclo 
(20.2.1.1.1.0', heptacosa 3,5,8,10,12,14(19), 15, 17, 
20,22,24-undecaene (100 mg., 0.16 mmol), lutetium (III) 
nitrate hydrate (177 mg, 0.47 mmol) and triethylamine (10 
drops) were combined in 150 mL of refluxing methanol for 
12-24 hours. The dark green reaction mixture was concen 
trated on a rotary evaporator to dryness and dried in vacuo 
for 24 hours. The crude complex was dissolved in a 100 mL 
1:1 (v/v) mixture of chloroform and methanol, filtered 
through celite and concentrated to 20 mL. A small amount 
of silica gel (approx. 3 grams) was added to the flask and 
then the dark green solution was carefully concentrated to 
dryness on a rotary evaporator. The silica was dried for 2 
hours in vacuo, then it was loaded on a chloroform packed 
silica column and the complex was purified by first using 
neat chloroform and then increasing concentrations of 
methanol in chloroform (0%-20%) as eluents. The dark 
green band collected from the column was concentrated to 
dryness on a rotary evaporator and recrystallized from 
chloroform/methanol/diethyl ether to yield 50 mg (ca. 35%) 
of the lutetium (III) B2 texaphyrin. For the LU (III) com 
plex: 'H NMR (CDC1/CDOH) 8: 1.82–1.91 (m, 12H, 
CHCH.), 2.39 (m, 4H, OCHCHCHOH), 3.32 (m, 4H, 
OCHCHCHOH), 3.39 (s, 6H, pyrr-CH), 3.92-4.04 (m, 
12H, OCHCHCH-OH and CHCH), 9.52 (s, 2H, 
CH=C), 10.24 (s, 2H, ArH), 12.23 (s, 2H, CH=N); 
UV/vis: 4200, 477.5, 730.0; FAB MSM811. 
Otherlanthanide and rare earth-like metal complexes may 
be synthesized in a similar manner including the La", Nd", 
Sm', Eu", Gd, Dy" and Tm complexes. 
EXAMPLE 4 
Synthesis of B2T2 TXP, see FIG. 7. 
2,5-Bis(5-benzyloxycarbonyl-4-methyl-3-methoxycar 
bonylethylpyrrol-2-yl)methyl-3,4-diethylpyrrole. 7, FIG. 
7. In a 500 mL round bottom flask was placed 250 mL of 
ethanol from an unopened bottle and this was then purged 
with dry nitrogen for ten minutes. 3,4-Diethylpyrrole 7 
(1.29 g, 0.01 mol) and 2-acetoxymethyl-5benzyloxycarbo 
nyl-4-methyl-3methoxycarbonylethylpyrrole 7A (7.83 g, 
0.02 mol) were added and the mixture heated until all of the 
pyrroles dissolved. p-Toluenesulfonic acid (65 mg) was 
added and the reaction temperature maintained at 60° C. The 
reaction slowly changed color from a clear yellow to a dark 
red with the product precipitating out of the solution as the 
reaction progressed. After ten hours the reaction was cooled 
to room temperature, the volume reduced to one half on a 
rotary evaporator, and then placed in the freezer for several 
hours. The product was collected by filtration, washed with 
a small amount of cold ethanol to afford 4.61 g of an off 
white fine powder (61%); H NMR (CDC), 250 MHz): a 
1.14 (6H, t, CHCH), 2.23 (6H, s, pyrrole-CH-), 2.31 (4H, 
t, CHCH-COCH), 2.50 (4H, q, CHCH), 2.64 (4H, t, 
CHCHCOCH), 3.60 (10H, brs, CHCO, and (pyrrole)- 
CH), 4.44 (4H, bris, CHCH), 6.99-7.02 (4H, m, aro 
matic), 7.22–7.26 (6H, m, aromatic), 8.72 (1H, s, NH), 10.88 
(2H, bris, NH); C NMR (CDC1, 250 MHz): 8 1097, 
16.78, 17.71, 19.40, 22.07, 35.09, 51.46, 65.32, 117.37, 
119.34, 122.14, 126.58, 126.79, 127.36, 128.19, 133.55, 
136,62, 162.35, 173.49; CI MS (M+H)"750; HRMS 
749.3676 (calc. for C.H.N.O. 749.3676). 
2,5-Bis(5-benzyloxycarbonyl-3-(3-hydroxypropyl)-4- 
methylpyrrol-2yl)methyl-3,4-diethylpyrrole. 7, FIG. 7. 
2,5-Bis (5-benzyloxycarbonyl-4-methyl-3methoxycarbon 














0.007 mol) was placed in a three necked 100 mL round 
bottom flask and vacuum dried for at least 30 minutes. The 
flask was equipped with a thermometer, an addition funnel, 
a nitrogen inlet tube, and a magnetic stir bar. After the 
tripyrrane was partially dissolved into 10 mL of dry THF, 29 
mL of borane (1MBH in THF) was added dropwise with 
stirring. The reaction became mildly exothermic and was 
cooled with a cool water bath. The tripyrrane slowly dis 
solved to form a homogeneous orange solution which turned 
to a bright fluorescent orange color as the reaction went to 
completion. After stirring the reaction for one hour at room 
temperature, the reaction was quenched by adding methanol 
dropwise until the vigorous effervescence ceased. The sol 
vents were removed under reduced pressure and the result 
ing white solid redissolved into CHCl2. The tripyrrane was 
washed three times with 0.5M HCl (200 mL total), dried 
over anhydrous KCO, filtered, and the CHCl removed 
under reduced pressure until crystals of the tripyrrane just 
started to form. Hexanes (50 mL) was added and the 
tripyrrane allowed to crystallize in the freezer for several 
hours. The product was filtered and again recrystallized from 
CH.Cl/ethanol. The product was collected by filtration and 
vacuum dried to yield 3.69 g of an orangish white solid 
(76%); mp 1729–173° C.; H NMR (CDC1, 300 MHz): a 
1.11 (6H, t, CHCH.), 1.57 (4H, p, CHCHCH-OH), 2.23 
(6H, s, pyrrole-CH), 2.39-249 (8H, m, CHCH and 
CHCHCH-OH), 3.50 (4H, t, CHCHCH-OH), 3.66 (4H, 
s, (pyrrole)-CH2), 4.83 (4H, s, CH-CH2), 7.17-7.20 (4H, 
m, aromatic), 7.25-7.30 (6H, m, aromatic), 8.64 (1H, s, 
NH), 9.92 (2H, s, NH); C NMR (CDC), 300 MHz): 
S10.97, 16.72, 17.68, 20.00, 22.38, 33.22, 62.01, 65.43, 
117.20, 119.75, 120,72, 122.24, 127.23, 127.62, 128.30, 
132.95, 136.60, 162.13; FAB MS (M) 693. 
2,5-Bis(3-(3-hydroxypropyl)-5-carboxyl-4-methylpyr 
rol-2-yl) methyl)-3,4-diethylpyrrole 7, FIG. 7. 2,5-Bis(3- 
(3 -hydroxypropyl)-5-benzyloxycarbonyl-4-methylpyrrol 
2-yl)methyl-3,4-diethylpyrrole 7 (15.0 g, 0.02 mol) was 
placed in a 1 L round bottom flask and dried in vacuo for ca. 
30 min. The tripyrrane was dissolved in dry THF (600 mL) 
with triethylamine (10 drops) and 10% Pd on carbon (600 
mg) and the reaction was stirred at room temperature under 
one atmosphere of H2. After 15 h, the suspension was 
filtered through celite to remove the catalyst and the result 
ing clear solution was concentrated under reduced pressure 
to yield a light pink solid. This material, obtained in near 
quantitative yield, was taken on to the next step without 
further purification. 
2,5-Bis(5-formyl-3-(3-hydroxypropyl)-4-methylpyrrol 
2-yl) methyl)-3,4-diethylpyrrole 7, FIG. 7. 2,5-Bis(3-(3 
-(hydroxypropyl)-5-carboxyl-4-methylpyrrol-2-yl)methyl)- 
3,4-diethylpyrrole 7 (10g, 0.02 mol) was placed in a 250 
mL round bottom flask and dried in vacuo for ca. 1 h. At 
room temperature under nitrogen, trifluoroacetic acid (31 
mL, 0.40 mol) was added dropwise via syringe. The tripyr 
rane dissolved with visible evolution of CO to form a 
homogeneous yellow solution. The reaction was stirred at 
room temperature for ca. 15 min, then cooled to -20° C. 
using a dry ice/CCl bath. Freshly distilled triethylorthofor 
mate (31 mL, 0.20 mol, dried over Cah) was added via a 
syringe to produce a dark orange/yellow solution. This 
mixture was stirred an additional 10 min at -20°C., then the 
cold bath was removed and 100 mL of distilled water was 
added dropwise to the solution. The resulting brown sus 
pension was stirred at room temperature for 15 min. The 
product was collected by filtration, washed several times 
with water and re-suspended into a 50 mL/100 mL/50 mL. 
(HO:EtOH:NHOH, viv) mixture. The yellow/brown sus 
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pension was stirred for 1 h, filtered, washed several times 
with water, and then rinsed with a small amount of cold 95% 
ethanol. At this point, TLC analysis shows a mixture of 
tripyrranes. Therefore, the crude dialdehyde tripyrrane and 
LiOH.HO (2.10 g, 0.05 mol) were added to 400 mL of 
degassed 95% MeOH and the suspension heated to reflux 
under a N atmosphere. The reaction became homogeneous 
when heated and after ca. 1 h, it was slowly cooled to room 
temperature. The reaction mixture was concentrated under 
reduced pressure to 75 mL and the resulting slurry placed in 
the freezer for several hours. The product was filtered and 
then purified by forming a slurry with 400 mL of methanol 
and 50 mL of water and heating close to boiling. The 
suspension was slowly cooled to room temperature, reduced 
to 150 mL under reduced pressure, and placed in the freezer 
for several hours. The purified dialdehyde tripyrrane was 
filtered, rinsed with water and dried in vacuo for 24 h to 
yield 7.65 g (80%) of a light tan powder. For 7: mp 
1649-166° C.; H NMR (CDD): 80.96 (t, 6H, CHCH.), 
1.49 (p, 4H, CHCHCH-OH), 2.25 (s, 6H, pyrr-CH), 
2.32-2.43 (m, 8H, CHCH and CHCHCH-OH), 3.46 (t, 
4H, CHCHCH-OH), 3.85 (s, 4H, (pyrr)2-CH2), 9.34 (s, 
2H, CHO): CIMS, M": m/e 480; HRMS, M: m/e 481.2942 




16,18,2022,24-undecaene (7 FIG. 7). 2.5-Bis(5-formyl 
3-(3-hydroxypropyl) -4 -methylpyrrol-2-yl) methyl-3,4- 
diethylpyrrole 7 (1.00 g, 0.002 mol) and 1,2-diamino-4, 
5-bis (3-hydroxy-propyloxy)benzene 7 (0.52g, 0.002 mol) 
were placed in a 2 L round bottom flask with 1000 mL of 
toluene and 200 mL of methanol. The solvents were purged 
with nitrogen prior to use. Concentrated HCl (0.5 mL) was 
added and the reaction heated to reflux under nitrogen. The 
reaction went from a clear suspension of starting materials 
to a dark red homogeneous solution as the reaction pro 
ceeded. After 5 h the reaction was cooled to room tempera 
ture and the solvents removed under reduced pressure until 
the product precipitated out of solution. The remainder of 
the solvent was decanted off and the macrocycle dried in 
vacuo. The dark red product was recrystallized from metha 
nol/diethylether and yielded 1.4-1.5g (90-100%). For 7. 
190° C. dec; H NMR (CDOD): 81.11 (t, 6H, CHCH), 
1.76 (p, 4H, pyrr-CHCHCH-OH), 2.03 (p, 4H, OCHCH 
CHOH), 2.36 (s, 6H, pyrr-CH), 2.46 (q, 4H, CHCH), 
2.64 (t, 4H, pyrr-CHCHCH-OH), 3.61 (t, 4H, pyrr 
CHCHCHOH), 3.77 (t, 4H, OCHCHCHOH), 4.10 (s, 
4H, (pyrr) 2-CH2), 4.22 (t, 4H, OCHCH-CHOH), 7.41 (s, 
2H, Ph.H), 8.30 (s, 2H, HC-N); CNMR (CDOD): 810.0, 
17.2, 18.6, 20.9, 24.5, 33.2, 33.5, 59.6, 61.9, 67.8, 107.1, 
120.7 123.8, 125.0, 125.8, 128.7, 144.8, 145.0, 150.7, 1546; 
UV/vis (CHOH) (, nm)365; FAB MS, (M+H)": m/e 
703; HRMS, M: m/e 701.4120 (calcd. for 
CHNO:701.4152). Anal. calcd. CHNO)(HCl) 
(CHOH): C, 63.92; H, 7.85; N, 9.09; Cl, 4.60. Found: C, 
64.17; H, 7.68; N, 9.39; Cl, 4.70. 
General procedure for the synthesis of water soluble 
lanthanide (III) 4,5-diethyl-10,23-dimethyl-9,24-bis (3-hy 
droxypropyl)-16, 17-(3-hydroxypropyloxy)-13,20,25,26,27 
pentaazapentacyclo[20.2.1.1.1'0''']heptacosa-1,3,5, 
7,9,11(27),12,14,16,18,20,22(25).23-tridecaene (7, FIG. 7). 




16,18,20,22,24-undecaene 7, 1.5 equivalents of the 
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Ln(NO).XHO metal salt, 2-3 equivalents of tetrabuty 
lammonium nitrate (TBANO) and triethylamine (ca. 1 mL) 
were mixed together in methanol and heated to reflux under 
air. After completion of the reaction (as judged by the 
UV/vis spectrum of the reaction mixture), the deep green 
solution was cooled to room temperature, the solvent 
removed under reduced pressure and the crude complex 













romethane/methanol (99:1 viv) was added to the crude 
complex and the suspension was sonicated a few min. The 
green suspension was filtered in order to remove red/brown 
colored impurities in the filtrate (incomplete oxidation prod 
ucts and excess triethylamine). The resulting deep green 
solid was first dissolved in methanol and then chloroform 
was added to reduce the polarity of the mixture (1:2 v/v). 
This solution was filtered through celite and loaded on a 
(pre-treated/pre-washed 1M NaNO) neutral alumina col 
umn (10 cm). The column was first eluted with a 1:10 (v/v) 
methanol/chloroform solution by gravity to remove a red 
dish brown impurity. The metal complex was then obtained 
by eluting the column with chloroform containing increasing 
amounts of methanol (20-50%). The purified lanthanide(III) 
texaphyrin complex was recrystallized by dissolving the 
complex in methanol/chloroform and carefully layering the 
dark green solution with a small amount of methanol, then 
with diethylether. The layered solution was kept at room 
temperature in the dark for a few days. Some of the 
lanthanide(HI) texaphyrin complexes formed single crystals 
by this method. Other complexes were recrystallized twice 
for analytically pure measurements and characterizations. 
Lanthanum(III) complex, 7. The hydrochloride salt of 
macrocycle 7 (300 mg, 0.407 mmol), La (NO)6H2O 
(350 mg, 0.814 mmol), TBANO (305 mg, 1.0 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 10 h. After workup using the general 
procedure outlined above, 132 mg of the complex was 
obtained (34%). For 7-ser HNMR (CDOD): a 1.68 (t, 
6H, CHCH.), 2.22–2.30 (m, 4H, pyrr-CHCHCH-OH and 
4H, OCHCHCHOH), 3.20 (s, 6H, pyrr-CH), 3.72-3.78 
(m, 4H, CHCH and 4H, pyrr-CHCHCH-OH and 4H, 
pyrr-CHCHCHOH), 3.94 (t, 4H, OCH2CHCH-OH), 
4.78 (m, 4H, OCH=CHCH-OH), 9.37 (s, 2H, ArH),9.87 
(s. 2H, (pyrr)C=CH), 11.71 (s, 2H, HC–N); C NMR 
(CDOD): 811.0, 18.9, 20.3, 23.0, 33.3, 36.3, 59.7, 62.2, 
68.1, 101.5, 118.5, 137.1, 140.3, 1446, 147.5, 148.2, 152.9, 
1549, 159.4; UV/vis: (MeOH) nm (log e): 355 
(4.34), 417 (4.73), 476 (5.06), 685.5 (408), 746 (4.59); FAB 
MS, M: m/e 835; HRMS, (M+H)+: m/e 836.2919 (calcd. 
for CHNO'Ce, 836.2903). Anal. calcd. for 
(CHNOCe(NO),(HO): C, 48.23; H, 5.47; N, 9.85. 
Found: C, 47.93; H, 5.41; N, 9.77. 
Cerium(III) complex 7. The hydrochloride salt of mac 
rocycle 7 (300 mg, 0.407 mmol), Ce (NO)6HO (265 
mg, 0. 611 mmol), TBANO (305 mg, 1.0 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 7 h. It is important to note that initially 
the reaction mixture formed a suspension, however, as the 
product formed the solution became homogeneous. After 
workup using the general procedure outlined above, 143 mg 
of dark green crystals were obtained (37%). This material 
was suitable for X-ray diffraction analysis. For 7x: UV/vis: 
(MeOH), nm (loge): 349.5 (4.34), 416.5 (4.70) 476.5 
(5.05), 684 (4.07), 741 (4.56); FAB MS, M": m/e 836; 
HRMS, (M+H)": me 836.2807 (calcd. for 
CHNO'Ce, 836.2816). Anal. calcd. for 
(CHNOCe(NO) (HO): C, 47.32; H, 5.56; N, 9.66. 
Found: C, 46.98; H, 5.22; N, 9.63. 
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Praseodymium(III) complex 7. The hydrochloride salt of 
macrocycle 7 300 mg, 0.407 mmol), Pr (NO3)4.5H2O 
(255 mg, 0. 611 mmol), TBANO (305 mg, 1.0 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 10 h. After workup using the general 
procedure outlined above, 200 mg of the complex was 
obtained (51%). For 7: UV/vis: (MeOH), nm (loge): 
352 (4.32), 416.5 (4.69), 476.5 (5.04), 689 (4.07), 744.5 
(4.57); FAB MS, M: m/e 838; HRMS, M+: m/e 837.2823 
(calcd. for CHNO'Pr, 837.2838). Anal. calcd. for 
(CHNOPr(NO)(CHOH) (HO): C, 48.65; H, 5.58; 
N, 9.69. Found: C, 48.75; H, 5.52; N, 9.71. 
Neodymium(III) complex 7. The hydrochloride salt 
macrocycle 7 (300 mg, 0.407 mmol), Nd(NO)6H2O(267 
mg, 0.611 mmol), TBANO (305 mg, 1.0 mmol) and tri 
ethylamine (ca. 0.5 mL) in 350 mL methanol were heated to 
reflux under air for 12 h. After workup using the general 
procedure outlined above, 125 mg of the complex was 
obtained (32%). For 7: UV/vis: (MeOH) nm (log 
e)):353.5 (4.32), 416 (4.68), 476 (5.05), 688 (4.06), 742.5 
(4.56); FAB MS, M": mile 839; HRMS, M+: m/e 838.2828 
(calcd. for CHNO'Nd, 838.2838). Anal. calcd. for 
CoHoNs)(CHOH): C, 49.48; H, 5.47; N, 9.86. 
Found: C, 49.23; H, 5.49; N, 9.83. 
Samarium(III) complex 7. The hydrochloride salt of 
macrocycle 7K (300 mg, 0.407 mmol), Sm(NO).5H2O 
(270 mg, 0.611 mmol), TBANO (305 mg, 1.0 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 7 h. After workup using the general 
procedure outlined above, 183 mg of a darkgreen crystalline 
solid was obtained (46%). This material has the potential for 
X-ray diffraction. For 7: UV/vis: (MeOH) nm (log 
e)): 354.5 (4.36), 415.5 (4.71), 475.5 (5.09), 682 (4.09), 741 
(461); FAB MS, M": m/e 849; HRMS, M": m/e 848. 2957 
(calcd. for CH5NO'Sm, 848. 2959). Anal. calcd. for 
CHNOSmI(NO)2(CHOH): C, 48.99; H, 5.42; N, 
9.76. Found: C, 48.79; H, 5.64; N, 9.43. 
Europium(III) complex 7. The hydrochloride salt of 
macrocycle 7 (400 mg, 0.543 mmol), Eu(NO). 5H2O 
(290 mg, 0.65 mmol), TBANO (500 mg, 1.64 mmol) and 
triethylamine (ca 1 mL) in 350 mL methanol were heated to 
reflux under air for 16 h. After workup using the general 
procedure outlined above, 255 mg of a darkgreen crystalline 
solid was obtained (48%). This material was suitable for 
X-ray diffraction analysis. For 70: UV/vis: (MeOH) , 
nm (log e)): 414 (4.72), 475.5 (5.10), 678 (408), 739.5 
(4.63); FAB MS, (M+H)": m/e 850; HRMS, M+: m/e 
849.2961 (calcd. for CHNOEu, 849.2974). Anal. 
calcd. for CHNO(NO)2(H2O): C, 47.56; H, 5.39;N, 
9.71. Found: C, 47.47; H, 5.45; N, 9.64. 
Gadolinium (III) complex 7. The hydrochloride salt of 
macrocycle 7 (750 mg, 1 mmol), Gd(NO).5H2O(660 mg, 
1.5 mmol), TBANO, (930 mg 3.0 mmol) and triethylamine 
(ca. 1 mL) in 600 mL methanol were heated to reflux under 
air for 12 h. After workup using the procedure outlined 
above, the dark green complex was recrystallized from 
chloroform/methanol/diethylether to yield 700 mg (72%) of 
a deep green crystalline solid. X-ray quality single crystals 
were obtained by dissolving the complex in methanol/ 
chloroform and carefully layering the dark green solution 
with a small amount of methanol, then with diethylether. The 
layered solution was kept atroom temperature in the dark for 
a few days. For 7: UV/vis: (MeOH), nm (loge): 358 
(4.33), 416 (472), 478 (5.12), 678 (463). 737.5 (4.64); 
(HO) nm (log e)): 347 (4.43), 419 (4.75), 469 (5.08), 
740 (4.60). IR (KBr, cm, major peaks): v3299 (OH), 1647 














1290, 1221, 1098, 1082. FAB MS, M+: mile 854; HRMS, 
M: m/e 854.2989 (calcd. for CHNOGd, 854.300. 
Anal. calcd. for (CHNOGd(NO)2(CHOH)(H2O): 
C, 47.85; H, 5.49; N, 9.53. Found: C, 47.62; H, 5.37; N, 
9.54. NOTE: If the alumina is not pre-treated with a NaNO 
wash, the Gd(III) will not have two nitrate counter anions, 
instead it will have one nitrate and one chloride counter 
anion: Anal. calcd. for CHNOGd(NO)Cl(H2O): C, 
48.65; H, 5.51, N, 8.51, Cl, 3.59. Found: C, 48.21; H, 5.58; 
N, 8.34; C1, 3.62. 
Terbium(III) complex 7. The hydrochloride salt of mac 
rocycle 7 (300 mg, 0.407 mmol), Tb(NO)6H2O (276 
mg, 0.611 mmol), TBANO (305 mg, 1.64 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 12 h. After workup using the general 
procedure outlined above, 152 mg of the complex was 
obtained (38%). For 7Q: UV/vis: (MeOH), nm (log 
e): 353 (4.35), 414 (4.71), 4745 (5.09), 680 (408), 737 
(4.62); FAB MS, M: m/e 856; HRMS, M": m/e 855.3017 
(calcd. for C40H5ONO'Tb, 855.3015). Anal. calcd. for 
(C40H5NOTb)(NO)(CHOH) (H2O): C, 47.80; H, 
5.48; N, 9.52. Found: C, 48.11; H, 5.28; N, 9.75. 
Dysprosium(III) complex 7. The hydrochloride salt of 
macrocycle 7 (300 mg, 0.407 mmol), Dy(NO).5H2O 
(266 mg, 0.611 mmol), TBANO (305 mg, 1.64 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 5 h. After workup using the general 
procedure outlined above, 250 mg of the complex was 
obtained (62%). For 7: UV/vis: (MeOH) nm (loge): 354 
(4.32), 414 (4.68), 475 (5.07), 677.5 (403), 735.5 (4.60); 
FAB MS, (M+H)": m/e 861; HRMS, M": m/e 860.3048 
(calcd. for C4OHNODy, 860.3053). Anal. calcd. for 
(CHNODy(NO)(HO): C, 47.89; H, 5.23; N, 9.78. 
Found: C, 47.97; H, 5.22; N, 9.72. 
Holmium(III) complex 7s. The hydrochloride salt of 
macrocycle 7 (300 mg, 0.407 mmol), Ho(NO).5H2O 
(269 mg, 0.611 mmol), TBANO (305 mg, 1.64 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 12 h. After workup using the general 
procedure outlined above, 220 mg of the complex was 
obtained (55%). For 7s: UV/vis: (MeOH), nm (loge): 
354 (4.35), 414 (4.72), 475.5 (5.12), 677 (408), 734 (4.65); 
FAB MS, M": m/e 862; HRMS, M: m/e 861.3044 (calcd. 
for CHNO'Ho, 861.3064). Anal. calcd. for 
(CHNOHol(NO)(CHOH)(HO): C, 47.52; H, 5.45; 
N. 9.47. Found: C, 47.55; H, 5.26; N, 9.30. 
Erbium(III) complex 7. The hydrochloride salt of mac 
rocycle 7 (300 mg, 0.407 mmol), Er(NO).5H2O (270 mg, 
0.611 mmol), TBANO (305 mg, 1.64 mmol) and triethy 
lamine (ca. 0.5 mL) in 350 mL methanol were heated to 
reflux under air for 12 h. After workup using the general 
procedure outlined above, 143 mg of the complex was 
obtained (36%). For 7T: UV/vis: (MeOH) 2 nm (log 
e): 355.5 (4.36), 414.5 (4.72), 477 (5.13), 672 (408), 732 
(4.66); FAB MS, M': m/e 863; HRMS, M: m/e 865.3110 
(calcd. for CHNOEr, 862.3064). Anal. calcd. for 
CHNOEr(NO)(CHOH): C, 48.32; H, 5.34; N, 
9.63. Found: C, 48.14; H, 5.14; N, 9.55. 
Thulium(III) complex 7. The hydrochloride salt of mac 
rocycle 7 (300 mg, 0.407 mmol), Tm(NO).5H2O (274 
mg, 0.611 mmol), TBANO (305 mg, 1.64 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 22 h. After workup using the general 
procedure outlined above, 150 mg of the complex was 
obtained (37%). This complex is more difficult to purify due 
to its lower solubility in methanol/chloroform solutions, 
which leads to its lower yield. For 7: UV/vis: (MeOH) 
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nm (loge): 355.5 (4.36), 414.5 (472), 477 (5.13), 672 
(4.08), 732 (4.66); FABMS, M": m/e 866; HRMS, M": m/e 
865.3110 (calcd. for CHNOTm, 865.3103). Anal. 
calcd. for CH5NOTm) (NO)2(H2O): C, 46.82; H, 
5.31; N, 9.56. Found: C, 46.85; H, 5.23; N, 9.38. 
Ytterbium(III) complex 7. The hydrochloride salt of 
macrocycle 7H (300 mg, 0.407 mmol), Yb(NO).5H2O 
(274 mg, 0.611 mmol), TBANO (305 mg, 1.64 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 24 h. After workup using the general 
procedure outlined above, 220 mg of the complex was 
obtained (54%). For 7v: FABMS, M: m/e 870; HRMS, M: 
mile 870,3132 (calcd. for CHNO"'Yb, 870,3149). 
Lutetium(III) complex 7. The hydrochloride salt of 
macrocycle 7 300 mg, 0.407 mmol), Lu (NO).H2O (220 
mg, 0.611 mmol), TBANO (305 mg, 1.64 mmol) and 
triethylamine (ca. 0.5 mL) in 350 mL methanol were heated 
to reflux under air for 24 h. After workup using the general 
procedure outlined above, 150 mg of the complex was 
obtained (37%). This complex has very low solubility in 
methanol/chloroform solution. Almost half of the product 
remained on the column during purification. For 7: FAB 
MS, M: m/e 872; HRMS, M": me 871.3154 (calcd. for 
C4OHNO67Lu, 871.3169). 
Acid-catalyzed Schiff-base condensation between 7 and 
7 produced the so-called "sp" nonaromatic macrocycle 7 
in quantitative yield. Macrocycle 7 is quite stable, decom 
posing only slightly over a period of months when stored in 
freezer. Oxidation and metallation of 7 in the presence of 
1.5 equivalents of lanthanide(III) metal salt, triethylamine, 
and air in boiling methanol produces a deep green metal 
complex within 3-24 hours (as judged by UV-Vis) of 
reaction time. All the lanthanide(III) (La-Lu, except Pm) 
texaphyrin complexes 7-7 were isolated with unopti 
mized yields ranging from 34%-7.5%. Satisfactory spectro 
scopic and mass spectrometric data were obtained for all 
new compounds. Single crystals suitable for X-ray diffrac 
tion analysis of the Eu(III) and Gd(III) complexes 7 and 7, 
(see-FIG. 2), respectively, were obtained by dissolving each 
complex in MeOH/CHCl and layering with diethyl ether. 
EXAMPLE 5 
Synthesis of B4T2 TXP: 
1,2-Dihydroxy-4,5-dinitrobenzene. 8, FIG. 8. In a dry 
500 mL round bottom flask, 1,2-dimethoxy-4,5-dinitroben 
Zene (3.2g, 0.12 mmol) 8 was stirred vigorously in 40 mL. 
of glacial acetic acid at 30°C. Once a homogeneous solution 
200 mL of 48% HBr was added to the flask and the reaction 
was slowly heated to reflux. The reaction was complete as 
indicated by TLC after 4 hours. The work up involved 
pouring the cooled solution into 800 mL of ice water and 
then extracting the aqueous phase with CHCl (3x150 mL) 
in order to remove any organic impurities. The dinitro 
catechol was extracted out of the aqueous layer with ethyl 
acetate (3X150 mL). The combined ethyl acetate extracts 
were washed with water and brine (3x100 mL), then dried 
over MgSO and concentrated to an orange residue. 
Approximately 100 mL of dichloromethane was added to the 
residue and then placed in the freezer for several hours. The 
light yellow needles that formed were filtered and washed 
with dichloromethane to yield 2.37 g of product (84%). H 
NMR (d-acetone): 83.45 (OH), 7.42 (Ar–H); 'C NMR 
(d6-acetone): 8112.44, 137.00, 149.97, EIMS M200. 
1,2-Bis(2,3-dihydroxypropyloxy)-4,5-dinitrobenzene. 8, 
FIG. 8. 1,2-Dihydroxy-4,5-dinitrobenzene 8 (5.0 g, 22 















mmol) were refluxed for 48 hours in a solution of potassium 
hydroxide (4.4 g) in 1-butanol (100 mL) under a nitrogen 
atmosphere. The resulting mixture was concentrated under 
reduced pressure, and the dark residue was partitioned 
between 100 mL of THF and 100 mL of brine/50 mL water 
solution in a 500 mL separatory funnel. The mixture was 
allowed to separate and the aqueous phase was extracted 
with THF (2x100 mL). The combined THF extracts were 
washed with brine (2x50 mL), dried over MgSO and 
concentrated to an oily residue. Here, CHCl was added 
very carefully to insure precipitation of the crude product. 
After stirring for 15 minutes, the suspension was filtered 
with a medium glass fitted funnel and air dried for several 
minutes. The orange solid was taken up in 120 mL of CHCl 
and 80 mL of diethyl ether at reflux and hot filtered to 
remove some impurities. The crude product was dissolved in 
a mixture of acetone and methanol (sonication may be 
required), then 6 grams of deactivated silica gel was added 
to the orange solution. The slurry was concentrated to 
dryness and the orange solid was dried in vacuo for one hour. 
The orange solid was loaded on a packed deactivated silica 
gel column. The column was eluted starting with neat CHCl 
followed by CHCl with increasing concentration of metha 
nol (0-10%). After a bright yellow impurity (monoalkylated 
product) was removed a colorless product began to elute 
(using 8-10% methanol in CHCl eluents). Conversely, on 
TLC the product will elute faster than the bright yellow 
monoalkylated product. The purified dialkylated tetrahy 
droxy product can be recrystallized from acetone/diethyl 
ether to yield 2.60 grams (30%) of a light yellow fluffy solid. 
H NMR (d6-acetone): 82.95 (bs, 4H, OH), 3.69 (d, 4H, 
OCHCH(OH)CHOH), 4.06 (p, 2H, 
OCH,CH(OH)CHOH), 4.24 4.35 (m, 4H, OCHCH(OH) 
CHOH), 7.72 (s, 2H, Ar-H); C NMR (d-acetone): 
863.55, 70.89, 72.53, 109.99, 137.22, 152.77. CI MS 349. 
1,2-Diamino-4,5-bis ((2,3-dihydroxypropyl)oxy)ben 
Zene. 8, FIG.8. The diamine was obtained by reduction of 
the corresponding 1,2-bis (2,3-dihydroxypropyl)oxy)-4,5- 
dinitrobenzene (0.30 g, 0.86 mmol) with hydrazine hydrate 
(1 mL) and 10% palladium on carbon (50 mg) in 40 mL 
refluxing absolute ethanol. The resulting brown suspension 
bubbled for approximately 15-20 minutes and then turned 
colorless after 1 hour. At this point the reduction was 
deemed complete as judged by TLC (R=0.63, 100% metha 
nol). The reaction solution was hot filtered through celite 
into a dry flask, covered with aluminum foil, and then 
concentrated to a light yellowish oil. The diamine was taken 
to the next step without further purification. For B4 diamine: 
H NMR (CDOD): 83.54-3.58 (m, 4H, 
OCHCH(OH)CHOH), 3.803.85 (m, 6H, 
OCHCH(OH)CHOH), 6.39 (s, 2H, Ar-H); C NMR 




12, 14(19), 15,17.20,22,24-undecaene. Isp B4T2 TXP8, 
FIG. 8. 2,5-Bis(5-formyl-3-hydroxypropyl-4-methylpyrrol 
-2-yl)methyl-3,4-diethylpyrrole (336 mg, 0.70 mmol) and 
1,2-diamino-4,5-bis((2,3-dihydroxypropyl)oxy)benzene (ca 
223 mg, 0.77 mmol) were placed in a 1 L round bottom flask 
with 600 mL of toluene and 175 mL of methanol. The 
solvents were purged with nitrogen prior to use. Concen 
trated HCl (ca 3 drops) was added and the reaction heated to 
reflux under nitrogen. After one hour the reaction was cooled 
to room temperature and the solvent removed under reduced 
pressure until the dark brown product precipitated. The 
remainder of the solvent was decanted off and the product 
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dried in vacuo. The product was used in the next step 
without further purification. 
Gadolinium (Iil) complex of 4,5-Diethyl-9,24-his (3-hy 
droxypropyl) -16,17-his ((2,3-dihydroxypropyl) oxy)-10, 
23-dimethyl-13,20,25,26,27-pentaazapentacyclo (20.2.1.1 
6.1.0'']heptacosa-1,3,5,7,9,11(27), 12,14(19), 15.17, 
20,22(25).23-tridecaene (GdB4T2Txpl. 8, FIG. 8. Two 
identical reactions containing a mixture of reduced B4T2 
texaphyrin ligand, 4,5-Diethyl-9,24-bis(3-hydroxypropyl)- 
16,17-bis( 2,3-dihydroxypropyl)oxy)-10,23-dimethyl-13, 
20.25, 26.27-pentaazapentacyclo[20.2.1. 1.1.0''' 
heptacosa -3,5,8,10,12,14(19), 15, 17.20,22,24-undecaene, 
(0.75 g, 0.001 mol), gadolinium (III) acetate tetrahydrate 
(1.19 g, 0.003 mol), and triethylamine (ca 1 mL) were heated 
at reflux under air in 750 mL of absolute methanol. After 
heating for 17 hours the reactions were cooled slightly and 
air bubbled through the reaction mixture for several minutes. 
The reactions were then heated to reflux again. After heating 
for a total of 21 hours the reactions were cooled to room 
temperature, the solvent removed on a rotary evaporator, and 
the dark green products combined and dried in vacuo for 
several hours. The metal complex was dissolved into 100 
mL of methanol and 6-8 grams of deactivated silica gel was 
added. (The silica gel was deactivated by adding a mixture 
of 6 mL water in 20 mL of methanol to 100 g of silica gel. 
After thorough mixing, the silica gel was allowed to air dry 
for 12 hours before bottling). The solvent was carefully 
removed on a rotary evaporator and the silica/complex 
mixture dried in vacuo for one hour. The complex was 
loaded onto a prepacked column of deactivated silica gel (5 
cm length)x3.5 cm diameter) and eluted with chloroform 
containing increasing amounts of methanol (0-80%). Frac 
tions containing the complex were collected and concen 
trated to dryness. The green complex was further purified by 
recrystallization from methanol/anhydrous ethyl ether. 480 
mg of product was obtained from the two combined reac 
tions (25%). For the complex: UV/vis, nm (CH4OH) 
415, 474, 740; FAB MS (M+H)"887; HR MS (M+H) 
887.2977 (calc for CHNOGd, 887.2981). 
EXAMPLE 6 
Further derivatives of Texaphyrin. 
Intermediates hydroxylated in various positions can be 
combined to effect the synthesis of a number of compounds. 
For example, the B4 TXP derivative is synthesized by 
reacting the intermediate compound 6 from FIG. 6 with 
compound 8 of FIG. 8. This constructs a molecule without 
hydroxyl groups on the tripyrrole moiety but with 4 
hydroxyl groups on the benzene ring moiety. 
The molecule T2 TXP is synthesized by reacting inter 
mediate 7 in FIG. 7 with 4,5-dimethyl-1,2-phenylenedi 
amine to yield a texaphyrin derivative with two hydroxyls 
on the tripyrrole portion of the molecule and no hydroxyl 
substituents on the benzene ring. 
A heptahydroxylated target B4T3 TXP is obtained by 
using the appropriate derivative 3-hydroxypropyl-4-meth 
ylpyrrole of the pyrrole (structure 7 of FIG.7) to make the 
trihydroxylated tripyrrole precursor which is then reacted 
with compound 8 of FIG. 8. 
FIGS. 11-19 provide specific examples of how one 
skilled in the art could extend and refine the basic synthetic 
chemistry outlined in this application so as to produce other 
hydroxylated texaphyrins equivalent in basic utility to those 
specifically detailed in the examples. FIG. 11 summarizes 
the synthesis of polyether-linked polyhydroxylated texaphy 













benzene diol) texaphyrin derivatives bearing further 
hydroxyalkyl substituents off the tripyrrane-derived portion 
of the macrocycle. FIG. 13 provides an example of a 
saccharide substituted texaphyrin in which the saccharide is 
appended via an acetal-like glycosidic linkage. An oligosac 
charide or a polysaccharide may be similarly linked to a 
texaphyrin. FIG. 14 summarizes the synthesis of a doubly 
carboxylated texaphyrin system in which the carboxyl 
groups are linked to the texaphyrin core via aryl ethers or 
functionalized alkyl substituents. The products of this 
scheme, compounds 14 H and 14 J could be converted to 
various esterified products wherein the ester linkages serve 
to append further hydroxyl-containing substituents. FIG. 15 
summarizes the synthesis of polyhydroxylated texaphyrin 
derivatives via the use of secondary amide linkages. FIG. 16 
summarizes the synthesis of another set of polyhydroxyl 
substituted texaphyrin derivatives using similar amide bonds 
as in FIG. 15. FIG. 17 summarizes the synthesis of saccha 
ride substituted texaphyrins, wherein the saccharide moi 
eties are appended via amide bonds. FIG. 18 summarizes the 
synthesis of polyhydroxylated texaphyrin derivatives con 
taining branched polyhydroxyl (polyol) subunits appended 
to the texaphyrin core via aryl ethers. FIG. 19 summarizes 
how similar polyol subunits may be appended via ester 
linkages. 
EXAMPLE 7 
Derivatives of Texaphyrin having Different R Groups on the 
B Portion of the Molecule. 
Texaphyrin macrocycles having a free carboxyl or a free 
amino group for further derivatization on the benzene ring 
portion of the molecule may be synthesized by replacing 
orthophenylenediamine with 3,4 diaminobenzoic acid or 3,4 
diaminoaniline (FIG. 9). One skilled in the art of organic 
synthesis would realize that other substituted 1,2-o-phe 
nylenediamines may be used as a precursor, e.g., a 1-2-o- 
phenylenediamine that is differentially substituted in the 4 
and 5 positions. This substitution may be the result of 
different functionalities being present or specific protection 
and standard organic and/or biochemical transformations 
having been carried out. Such macrocycles can be further 
functionalized to the derivatives shown in FIG. 10. 
The Synthesis of Aminosugar-Texaphyrin Conjugates by 
Ester-to-Amide Exchange. The synthetic strategy used to 
prepare aminosugar-texaphyrin conjugates is based on an 
ester-to-amide conversion of an appropriate starting texa 
phyrin methyl ester derivative shown as "Method A' in FIG. 
10B. In a preferred embodiment, the texaphyrin methyl ester 
derivative contains this functionality on the benzene, or 
so-called "B", portion of the macrocycle and is linked to it 
by a spacer such as -OCH-. The amine used in the 
aminolysis is 1,2,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-a- 
D-glucopyranose hydrobromide. With such preferred start 
ing materials, one can achieve the desired ester to amide 
conversion by heating at reflux in an organic solvent such as 
methanol. Either during the course of this key synthesis step 
or as a separate transformation, the protecting groups on the 
sugar derivative are removed to yield the desired amino- . 
Sugar-texaphyrin conjugate. 
One of the advantages of this procedure is that the 
reaction is catalyzed by HBr normally complexed as its 
hydrobromide salt with the aminosugar component. Other 
advantages of this procedure are the solubility of both 
reaction components in methanol (or other organic solvents 
such as acetonitrile, DMF, DMSO, which one skilled in the 
art would appreciate can be used in place of methanol) and 
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the high yield obtained in the coupling step. Finally, and 
perhaps most importantly, the resulting products are not only 
quite stable, they are also highly soluble in aqueous solution. 
The same procedure is applicable for other aminosugars, 
such as galactosamine, mannosamine, and aminooligosugar 
derivatives, as described in the following example. 
The preparation of GdT2B (OCH2CONHR) where R is 
glucosamine: A Texaphyrin-glucosamine Conjugate. The 
dihydroxyl, methyl ester substituted texaphyrin referred to 
as GdT2B(OCH2COCH) and shown as the starting mate 
rial in FIG. 10B (91.2 mg. 0.1 mmol) was dissolved in 
absolute methanol under nitrogen. Tetra-O-acetylglu 
cosamine hydrobromide (50 mg. 0.12 mmol) was added. 
The reaction mixture was subsequently heated at reflux 
under nitrogen for 6 hours before being allowed to cool to 
room temperature. After reaching room temperature (RT), 
the methanol was evaporated off under vacuum, the residue 
was resuspended in 50 ml of dichloromethane and stirred for 
2 hours using a magnetic stirrer at RT. Any remaining free 
Gd(III) salts were removed using a zeolite with an appro 
priately sized set of cavities as the trapping agent. This was 
done by dissolving the crude productin methanol containing 
10% water by volume, shaking for 10 hours with 5g of the 
selected zeolite, filtering off the zeolite (now containing any 
free Gd(III) ions), and redrying under vacuum. The resulting 
product was then recrystallized from methanoldichlo 
romethane (1:3 by volume). The yield of product so obtained 
is 99 mg, giving an overall yield of 85% for the combined, 
coupling, deprotection and purification steps. Characteriza 
tion data: MS: FAB: 946 (MH.". HR MS: For 
CHNOGd calcd.946. 33524. Found 946. 33486. UV 
Vis (HO): 450,762. 
Preparation of Oligopeptide-Texaphyrin Conjugates by 
Ester Saponification Followed by Carbodiimide Coupling. 
Starting from the same preferred texaphyrin methyl ester 
considered in the previous example, oligopeptide-texaphy 
rin conjugates may also be prepared. Here, as shown as 
Method B in FIG. 10B, the preferred embodiment entails an 
ester saponification step to liberate the free acid, followed by 
carbodiimide mediated condensation with the free amine 
group of an appropriate oligopeptide. In the preferred 
embodiment, the amine-containing oligopeptide is polyl 
ysine. Preferred coupling reagents are carbonyldiimidazole, 
mixed anhydrides, activated esters such a p-nitrophenyl, or 
NHS (N-hydroxysuccinimide) and the preferred reaction 
conditions are at neutral or near-neutral buffered aqueous 
solutions. The same procedure may be used to conjugate 
other oligopeptides such as (LysAla)n, (LysLeuAla)n, poly 
glutamic acid, polyornithine, oligosaccharides or polysac 
charides such as heparin and the like to texaphyrins, as one 
skilled in the art can appreciate from the specific teachings 
contained in the example given below. 
This procedure yields a texaphyrin derivative with desir 
able, high water solubility properties and allows for the 
possibility of specific targeting to different cells as a result 
of inherent protein-oligosaccharide immunological interac 
tions. Since cancer cells display significant differences in the 
composition of their cell surface oligosaccharides as com 
pared to normal cell membranes, these cancer cell surface 
oligosaccharides are expected to interact with peptides in a 
different way as compared to normal ones. The presently 
described approach may allow for the design of texaphyrin 
oligopeptide (or texaphyrin-protein) conjugates that are 
selective for cancer cells as a result of these differential 
oligosaccharide-oligopeptide interactions. 
Synthesis of Texaphyrin-poly-L-Lysine. The dihydroxyl, 















GdT2B(OCH2COCH) and shown specifically as the start 
ing material in FIG. 10B (91.2 mg. 0.1 mmol) was dissolved/ 
suspended in 3 ml of a 1M aqueous solution of a triethy 
lammonim hydrogen carbonate buffer, pH 8.5, and stirred at 
RT for 2 days. (At this point, the hydrolysis/saponification of 
the ester was complete, as judged by MS and HPLC analy 
sis). The solution was then cooled to 0° C. and the carbo 
diimide known as EDC (25 mg, 0.13 mmol) was added with 
stirring and the solution stirred at 0°C. for an additional 45 
minutes. At this time, a solution (2 ml) of poly-L-lysine in 
water was added. The resulting mixture was then stirred for 
an additional 1 hour at 0°C. followed by an additional 1 day 
at RT. Following this, an additional equivalent of EDC (19.1 
ng, 0.01 mmol) was added and again the mixture was 
allowed to stir at room temperature, this time for 2 days. 
Following this, the water was removed by evaporation under 
vacuum followed by trituration with and subsequent in 
vacuo removal of toluene (3x20 ml). The resulting material 
was then washed with dichloromethane (30 ml) and dried 
under vacuum overnight. The product obtained in this way 
(93% yield) displays the characteristic UV-Vis spectrum of 
a metallated texaphyrin (A:452,762 rim). 
The Synthesis of Aminosugar-Texaphyrin and Oligopep 
tide Texaphyrin Conjugates by Carbodiimide Mediated 
Reaction with Carboxy-Substituted Texaphyrins. Both ami 
nosugar-texaphyrin and oligopeptide-texaphyrin conjugates 
may be readily prepared using a carbodiimide mediated 
condensation of an aminosugar or an amine-containing 
oligopeptide, as appropriate, with a carboxy-substituted 
texaphyrin. In a preferred embodiment, the carboxy-substi 
tuted texaphyrin would contain this functionality on the 
benzene or so-called 'B' portion of the macrocycle. Pre 
ferred coupling reagents would be carbonyldiimidazole, 
mixed anhydrides, activated esters such as p-nitrophenyl, or 
NHS (N-hydroxysuccinimide) and the preferred reaction 
conditions would be neutral or near-neutral buffered water 
solutions, DMF, or water-DMF mixtures. 
This procedure may be used to conjugate oligopeptides 
such as (LysAla), (LysLeuAla), polyglutamic acid, poly 
ornithine and the like to texaphyrins as well as other 
aminosugars, such as galactosamine, mannosamine, and 
amino-oligosugar derivatives. This procedure may general 
ized to prepare desired conjugates or congeners thereof 
using carboxy-substituted texaphyrins where the substituent 
is found elsewhere in the molecule. The following proce 
dures, "Method A' and "Method B' refer to synthesis 
Schemes in FIG. 10C. 
Method A. In this method, 1,1'-carbonyldiimidazole is 
used as a coupling reagent: 1 mol. eq. of the carboxy 
substituted texaphyrin shown in FIG. 10C (TX-CO2H) was 
dissolved in dry DMF. 1.1 mol. eq. of 1,1'-carbonyldiimi 
dazole was added and the resulting mixture stirred under 
argon for 4 hours. The amino-component (1 mol. eq.) was 
dissolved in water-pyridine mixture (10:1), or in buffer (pH 
8.5 or higher for optimum yields in the coupling) and slowly 
added to the solution of the now-activated carboxy-substi 
tuted texaphyrin component. The resulting reaction mixture 
was stirred at RT for 1-5 days (the reaction could be 
followed by HPLC analysis) or at 37° C. for 24 hours 
followed by evaporation at high vacuum, chromatographic 
purification, and/or recrystallization. 
Method B. This method uses the carbodiimide known as 
EDC as the coupling reagent. The texaphyrin acid, 
TX-CO2H, (1 mol. eq.) was dissolved in dry DMF. The 
resulting solution was then cooled to 0°C. At this point the 
EDC carbodiimide (1.5 mol, eq.) and 3 mg of 1-hydroxy 
benzotriazole were added. The resulting mixture was then 
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stirred at this temperature for 40 min. To the resulting 
solution, the amine containing component (1 mol. eq.) was 
added in aqueous buffer (pH 8.5). The resulting solution was 
kept at 0° C. for 1 hour and then stirred at RT for 2-5 days, 
with the course of the reaction being followed by HPLC, or 
reverse TLC. Following removal of solvent, the product was 
isolated by preparative HPLC. 
EXAMPLE 8 
A Derivative of Texaphyrin having an R Group on a Ring 
Nitrogen. 
A further texaphyrin macrocycle is one in which a ring 
nitrogen is derivatized. FIG. 20 shows such an N-substituted 
texaphyrin where an R group is attached to the central 
nitrogen of the precursor tripyrrole. R may be a lower alkyl 
group, preferably a methyl group. The free base macrocycle 
would be particularly useful when fluorescence detection is 
used as the localization means for radiosensitization. Optical 
characteristics of various texaphyrin complexes are 
described in Sessler et al. (1991), incorporated by reference 
herein. 
EXAMPLE 9 
Derivatives of Texaphyrin having Four or more Hydroxyl 
Groups on the Tripyrrole Portion of the Molecule. 
Preparation of T4 tripyrrane dialdehyde, serinol derived, 
FIG. 21A. A tripyrrane dialdehyde 21 having four 
hydroxyls on the periphery may be synthesized as indicated 
in FIG. 21A using the dicarboxylic acid derived tripyrrane 
dialdehyde 21 and serinol 21 upon initial in situ activation 
with 1,1-carbonyldiimidazole. 
Preparation of T4 tripyrrane dialdehyde, diethanolamine 
derived FIG. 21.B. A tripyrrane dialdehyde 21 having four 
hydroxyls on the periphery may be synthesized as indicated 
in FIG. 21B using the dicarboxylic acid derived tripyrrane 
dialdehyde 21 and diethanolamine 21 upon initial in situ 
activation with 1,1-carbonyldiimidazole. 
Preparation of T8-T1O tripyrrane dialdehyde, FIGS. 22 
and 23, glucosamine derived. A tripyrrane dialdehyde 22 
having eight hydroxyls on the periphery may be synthesized 
as indicated in FIG. 22 using the dicarboxylic acid derived 
tripyrrane dialdehyde 21 and D-glucosamine hydrochloride 
22 upon initial in situ activation with 1,1-carbonyldiimi 
dazole. 
Preparation of T8-T1O tripyrrane dialdehyde, N-methyl 
glucamine derived. A tripyrrane dialdehyde 23 having ten 
hydroxyls on the periphery may be synthesized as indicated 
in Figure23 using the dicarboxylic acid derived tripyrrane 
dialdehyde 21 and N-methyl-D-glucamine 23 upon initial 
in situ activation with 1,1-carbonyldiimidazole. 
One skilled in the art would understand that depending on 
the nature of the linking group, the saccharide moiety may 
be in equilibrium between the straight chain form and the 
pyranose form of the molecule, therefore between 8-10 free 
hydroxyls may be present on the molecule at equilibrium. 
Representative diamines for reacting with dialdehydes to 
synthesize texaphyrin macrocycles are shown in FIG. 24. 
Preparation of a T4 macrocycle. A texaphyrin macrocycle 
having four hydroxyls on the tripyrrane portion of the 
molecule may be synthesized as indicated in FIG. 9 using 
the tripyrrane dialdehyde 21 and the diamine 24A to form 
25A (FIG. 25A); 21 may be combined with 24 to form 
25, 21 may be combined with 24 or 24 to form 25, or 
25, T4 macrocycles. 
Preparation of a T6 macrocycle. The tripyrrane dialde 














(FIG. 26A), a texaphyrin with 4 hydroxyls on the Tportion 
and 2 on the B portion of the molecule. Similarly, reaction 
with diamine 24 would yield a B2T4 macrocycle one 
carbon chain longer at positions Rs and R (FIG. 9, FIG. 
26A). 
Tripyrrane dialdehyde 21 may be reacted with diamine 
24 to form 26 or diamine 24 to form 26, a T4 or a T4B2 
macrocycle, respectively. In structure 24 or 24, n is a 
whole number between 0 and 100. Tripyrrane dialdehyde 
21 may be combined with 24 or 24 to form 26 or 26, 
T4B2 macrocycles (FIG. 26A). 
Tripyrrane dialdehyde 21 may be combined with 24 or 
24 to form 26 or 26, a T4 or a T4B2 macrocycle, 
respectively (FIG. 26A). 
Preparation of T8-T12 macrocycles. Tripyrrane dialde 
hyde 22 may be reacted with 24 or 24 to form 27A or 27, 
(FIG. 27A). Tripyrrane dialdehyde 22 may be reacted with 
24 or 24 to form 28 or 28, (FIG. 28A). Tripyrrane 
dialdehyde 22 may be reacted with 24 or 24 to form 28A 
or 28 (FIG. 28A). Tripyrrane dialdehyde 23 may be 
reacted with 24 or 24 to form 29 or 29 (FIG. 29A). 
Tripyrrane dialdehyde 23 may be reacted with 24 or 24 
to form 30 or 3% (FIG. 30A). Tripyrrane dialdehyde 23 
may be reacted with 24 or 24 to form 30 or 30 (FIG. 
30A). 
EXAMPLE 10 
Texaphyrin Conjugates to Site-Directed Molecules for Radi 
osensitization and Texaphyrins as an Internal Radioactive 
Source 
The use of texaphyrins as radiosensitizers in vivo as part 
of a treatment procedure relies on the effective localization 
of the complex to the treatment site. This localization may 
occur by conjugating the texaphyrin metal complex to a 
site-directed molecule such as an antibody, a peptide having 
affinity for a biological receptor, to a dye or other compound 
having binding specificity for a target, to a sequence-specific 
oligonucleotide, or localization may rely on the intrinsic 
biolocalization properties of the texaphyrins as discussed in 
Example 11. 
Texaphyrins are especially suited for acting as bifunc 
tional chelating agents in antibody conjugate-based treat 
ment since they have functional groups suitable for conju 
gation to the antibody. They form covalent linkages that are 
stable in vivo which do not destroy the immunological 
competence of the antibody, they are relatively nontoxic, 
they bind metals and retain the metal of interest under 
physiological conditions, and they are readily soluble in a 
physiological environment. A further advantage of these 
texaphyrins is that many would be suitable for further 
functionalization. Treatment of carboxylated texaphyrins 
with thionyl chloride or p-nitrophenol acetate would gener 
ate activated acyl species suitable for attachment to mono 
clonal antibodies or other biomolecules of interest. Standard 
in situ coupling methods (e.g. 1,1'-carbonyldiimidazole 
(CDI) could be used to effect the conjugation. 
The selectivity of the texaphyrins may be enhanced by 
covalently linking oligonucleotides onto the periphery of the 
macrocycle. Amides, ethers and thioethers are representative 
of linkages which may be used for this purpose (see FIG. 
10). Oligonucleotides functionalized with amines at the 
5'-end, the 3'-end, or internally at sugar or base residues may 
be modified post-synthetically with an activated carboxylic 
ester derivative of the texaphyrin complex. Alternatively, 
oligonucleotide analogs containing one or more thiophos 
phate or thiol groups may be selectively alkylated at the 
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sulfur atom(s) with an alkyl halide derivative of the texa 
phyrin complex. The resultant oligodeoxynucleotide-com 
plex conjugates may be designed so as to provide optimal 
catalytic interaction between a target nucleic acid and the 
bound texaphyrin. The oligonucleotide may be large enough 
to bind probably at least 15 nucleotides of complementary 
nucleic acid. 
A general method for preparing oligonucleotides of vari 
ous lengths and sequences is described by Caracciolo et al. 
(1989) Science, 245:1107. 
In general, there are two commonly used solid phase 
based approaches to the synthesis of oligonucleotides con 
taining conventional 5'-3' linkages, one involving interme 
diate phosphoramidites and the other involving intermediate 
phosphonate linkages. In the phosphoramidite synthesis a 
suitably protected nucleotide having a cyanoethylphospho 
ramidate at the position to coupled is reacted with the free 
hydroxyl of a growing mucleotide chain derivatized to a 
solid support. The reaction yields a cyanoethylphosphite, 
which linkage must be oxidized to the cyanoethylphosphate 
at each intermediate step, since the reduced form is unstable 
to acid. 
The phosphonate based synthesis is conducted by the 
reaction of a suitably protected nucleotide containing a 
phosphonate moiety at a position to be coupled with a solid 
phase-derivatized nucleotide chain having a free hydroxyl 
group, in the presence of a suitable activator to obtain a 
phosphonate diester linkage, which is stable to acid Thus, 
the oxidation to the phosphate or thiophosphate can be 
conducted at any point during synthesis of the oligonucle 
otide or after synthesis of the oligonucleotide is complete. 
The phosphonates can also be converted to phosphora 
midate derivatives by reaction with a primary or secondary 
amine in the presence of carbon tetrachloride. To indicate the 
two approaches generically, the incoming nucleotide is 
regarded as having an "activated' phosphite/phosphate 
group. In addition to employing commonly used solid phase 
synthesis techniques, oligonucleotides may also be synthe 
sized using solution phase methods such as triester synthe 
sis. The methods are workable, but in general, less sufficient 
for oligonucleotides of any substantial length. 
Preferred oligonucleotides resistant to in vivo hydrolysis 
may contain a phosphorothioate substitution at each base (J. 
Org. Chem, 55:4693-4699, (1990) and Agrawal, (1990). 
Oligodeoxynucleotides or their phosphorothioate analogues 
may be synthesized using an Applied Biosystem 380B DNA 
synthesizer (Applied Biosystems, Inc., Foster City, Calif.). 
Another means of gaining selectivity may be to covalently 
link the texaphyrin complex to a sapphyrin (sap) molecule, 
(Sessler et al., 1992; Furuta et al., 1991; Sessler et al., 1991; 
U.S. Pat. Nos. 5,159,065; 5,120,411; 5,041,078). Since 
sapphyrins bind DNA, K-10M, (U.S. Ser. No. 07/964, 
607, incorporated by reference herein) the linked texaphy 
rin-sapphyrin complex (txph-sap) could effectively increase 
the texaphyrin concentration at locations adjacent to the 
sapphyrin binding sites. Sapphyrins have a higher fluores 
cent quantum yield than texaphyrins, allowing greater fluo 
rescence detection. A laser system may be employed where 
the molecules are optimized to the laser wavelength; an 
excited sapphyrin may transfer its energy to the conjugated 
texaphyrin for detection. The texaphyrin molecule may 
further be designed to pass through cell membranes for 
selective radiosensitization. 
Radioisotopes play a central role in the detection and 
treatment of neoplastic disorders. Improving their efficacy in 
medical applications involves attaching radioisotopes to 














bodies could serve as "magic bullets' and allow the direct 
transport of radioisotopes to neoplastic sites thus minimizing 
whole body exposure to radiation. The use of bifunctional 
metal chelating agents in radioimmunodiagnostics (RED), 
radiosensitization and therapy (RIT) is most closely related 
to the present invention. In these procedures, the radiometal 
of interest must be bound and retained under physiological 
conditions. The potential damage arising from "free' radio 
isotopes, released from the complex, can be very serious. 
The advantage of a chelate, such as a texaphyrin metal 
complex, that does not allow for metal release is clear. 
For the purposes of imaging, an ideal isotope should be 
readily detectable by available monitoring techniques and 
induce a minimal radiation-based toxic response. In practice 
these and other necessary requirements implicate the use of 
a Y-ray emitter in the 100 to 250 KeV range, which possesses 
a short effective half-life (biological and/or nuclear), decays 
to stable products, and, of course, is readily available under 
clinical conditions. To date, therefore, most attention has 
focused on 'I (t=193h), 'I (t=13h), ''"Tc(t=6.0 
h), '', 4=78h), and 'In?t=67.4h) which come closest 
to meeting these criteria. Each of these enjoys advantages 
and disadvantages with respect to antibody labeling for RID. 
'I and 'I, for instance, are easily conjugated to antibod 
ies via electrophilic aromatic substitution of tyrosine resi 
dues. The metabolism of 'I or 'I labeled proteins, 
however, produces free radioactive iodide anion and as a 
result can lead to a fair concentration of radioactivity at sites 
other than those targeted by the antibody-derived "magic 
bullet'. The half-lives of both 'I and 'I are relatively 
inconvenient for optimal use, being too long and too short, 
respectively, and the fact that 'I is also a B emitter.'"Tc, 
Ga, and 'In all suffer from the disadvantage that they 
cannot be bound directly to the antibody in a satisfactory 
fashion and require the use of a bifunctional conjugate. The 
chemistry of such systems is furthest advanced in the case of 
"Tc, and a number of effective ligands, are now available 
for the purpose of "Tc administration. This radioisotope 
has a very short half-life which makes it technically very 
difficult to work with. Both 'Ga and 'In have longer 
half-lives and possess desirable emission energies. Both are 
"hard' cations with high charge density in their most com 
mon trivalent forms. No suitable ligands exist for either 
In or Ga" which form stable nonlabile complexes 
and which might be suitable for radioimmunological appli 
cations. As described elsewhere herein texaphyrin forms a 
kinetically and hydrolytically stable complex with In". 
Such a ligand system may be elaborated and serve as the 
critical core of a bifunctional conjugate for use in 'In 
based RID. 
Many of the same considerations hold true for radioiso 
tope-based therapy as do for radioisotope-based diagnostics: 
An ideal isotope must also be readily available under clinical 
conditions (i.e. from a simple decay-based generator), pos 
sess a reasonable half-life (i.e. on the order of 6 hours to 4 
weeks), and decay to stable products. In addition, the 
radioisotope must provide good ionizing radiation (i.e. in the 
300 KeV to 3 MeV range). A number of Bemitters, including 
'I, are currently receiving attention as possible candidates 
for RIT. Among the more promising, are Re (t=90 h, 
7Cu (t=58.5 h), and Y (t=65 h). Of these, 'Y is 
currently considered the best, with an emission energy of 
2.28 MeV, it is calculated to deliver roughly 3 to 4 times 
more energy (dose) to the tumor per nanomole than either 
'Re or "Cu. Good immuno-compatible chelands exist for 
only Re and Cu, the former may be attached using the 
same ligands as were developed for "Tc, and the latter via 
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the rationally-designed activated porphyrins developed by 
Prof. Lavallee of Hunter College and the Los Alamos 
INC-11 team. Further benefits should be derived from a 
bifunctional conjugate which is capable of forming stable, 
nonlabile complexes with 'Y' (which cannot be done with 
porphyrins). The texaphyrin ligand of the present invention 
not only forms stable complexes with In" but also binds Y' 
effectively. A texaphyrin-type bifunctional conjugate may be 
prepared for use in 'In-based RID and in Y-based RIT. 
Both 'Y and 'In could conceivably be attached to an 
antibody of choice using a functionalized texaphyrin. The 
Y and In" complexes of texaphyrin are formed rapidly 
(insertion and oxidation times are less than 3 hours) from the 
methylene-linked reduced precursor, and are hydrolytically 
stable in 1:1 methanol-water mixtures (the half-lives for 
decomplexation and/or ligand decomposition exceed 3 
weeks in both cases. "Gd is primarily a gamma emitter and 
is a preferred paramagnetic metal for magnetic resonance 
imaging. 'GdB2T2 localizes to the liver and would be a 
preferred metal complex for use as a tracer for pharmaco 
kinetic studies. 
The hydroxy-substituted texaphyrin molecules of the 
present invention are suited for delivering radioactivity to a 
tumor on their own since they chelate radioisotopes and 
have intrinsic biolocalization selectivity. This intrinsic 
biolocalization is described in Example ll. A texaphyrin 
complexed to Y may be administered in combination with 
another texaphyrin complexed to a diamagnetic metal for 
photodynamic tumor therapy, for example, to achieve a 
synergistic killing of malignant cells. 
EXAMPLE 11 
Hydroxy-Substituted Texaphyrins for Imaging. 
In many respects the key to cancer control lies in early 
detection and diagnosis as it does in Subsequent therapeutic 
management. New techniques which allow neoplastic tissue 
to be observed and recognized at an early stage of devel 
opment thus have a critical role to play in the battle against 
these disorders. One such promising technique is magnetic 
resonance imaging (MRI). Although quite new, this nonin 
vasive, apparently innocuous method, is now firmly 
entrenched as a diagnostic tool of prime importance, 
complementing or, in some cases, supplanting computer 
assisted X-ray tomography as the method of choice for solid 
tumor detection. 
The physical basis of current MRI methods has its origin 
in the fact that in a strong magnetic field the nuclear spins 
of water protons in different tissues relax back to equilibrium 
at different rates. When these local, tissue-dependent relax 
ation differences are large, tissue differentiation can be 
effected. Paramagnetic compounds, containing one or more 
unpaired spins, enhance the relaxation rates for the water 
protons in which they are dissolved. The extent of this 
enhancement is termed relaxivity. At present, only one 
paramagnetic MRI contrast agent is in clinical use, the 
bis(N-methyl-glucamine) salt of Gd(III) diethylenetriamine 
pentaacetate, (MEG)Gd(DTPA)(HO) marketed by Ber 
lex Laboratories. This dianionic complex localizes selec 
tively in extracellular regions, and is being used primarily in 
the visualization of the capillary lesions associated with 
cerebral tumors. 
Considerable effort has been devoted to the development 
of new potential MRI contrast agents. Most of this work has 
centered around preparing new complexes of Gd(III). The 
emphasis on Gd(III) salts stems from the fact that this cation, 














than other paramagnetic cations such as Fe(III) and Mn(II). 
Thus, complexes of Gd(III) would be expected to be supe 
rior relaxation agents than those derived from Mn(II) or 
Fe(III). In addition, both iron and, to a lesser extent, man 
ganese are sequestered and stored very efficiently in humans 
(and many other organisms) by a variety of specialized 
metal-binding systems. Moreover both iron and manganese 
are capable of existing in a range of oxidation states and are 
known to catalyze a variety of deleterious Fenton-type 
free-radical reactions. Gadolinium(III), which suffers from 
neither of these deficiencies, thus appears to offer many 
advantages. As is true for Fe(III) and Mn(II), the aqueous 
solution of Gd(III) is too toxic to be used directly for MRI 
imaging at the 0.01 to 1 mM concentrations required for 
effective enhancement. Hence the emphasis is on developing 
new agents which, as is true for DTPA, form hydrolytically 
stable complexes in vivo with Gd(III) and/or other para 
magnetic cations. A number of such ligands, including the 
very promising DOTA and EHPG systems, are now known. 
In almost all cases, however, reliance is made on the same 
basic philosophical approach. Specifically, for Gd(III) bind 
ing, carboxylates, phenolates, and/or other anionic chelating 
groups are being used to generate intrinsically labile com 
plexes of high thermodynamic stability in the hope that such 
high thermodynamic stability will translate into a kinetic 
stability that is sufficient for in vivo applications. Little effort 
is currently being devoted to the preparation of nonlabile 
Gd(III) complexes that would in and of themselves enjoy a 
high kinetic stability. The problem seems to be quite simply 
that such systems are hard to make. For instance, unlike the 
transition metal cations which are bound well to porphyrins 
(a synthetically versatile ligand which is readily subject to 
modification and which, at least for Mn(III)TPPS, and 
other water soluble analogues, shows good relaxivity and 
good tumor localizing properties), Gd(III) forms only weak 
and/or hydrolytically unstable complexes with porphyrins, 
although other simple macrocyclic amine- and imine-de 
rived ligands will support stable complexes with certain 
members of the lanthanide series and do show some prom 
ise, as yet unrealized, of acting as supporting chelands for 
Gd(III)-based MRI applications. 
According to the present invention nonlabile Gd(III) 
complexes of hydroxy-substituted texaphyrins prove to be 
useful contrast agents for MRI applications. Hydroxy-sub 
stituted texaphyrins are capable of stabilizing complexes 
with a variety of di- and trivalent cations, including Cd', 
Hg', Lu', Gd, and La". Such complexes are particu 
larly soluble in physiological environments. 
Magnetic Resonance Imaging with B2T2 in vivo 
The T2B2 gadolinium complex showed low toxicity and 
good tissue selectivity in magnetic resonance imaging 
enhancement. 
Imaging: Scanning was performed using a circumferential 
transmit/receive coil (Medical Advances, Milwaukee, 
Wisc.) in the bore of a 1.5 Tesla Signa scanner (GE Medical 
Systems, Milwaukee, Wisc.). Normal male Sprague-Dawley 
rats (n=5) weighing from 280–320 grams and rats bearing 
subcutaneously implanted methylcholanthrene-induced fib 
rosarcomas in their left flanks (n=4) were studied. Tumor 
size at the time of the study ranged from 2.5 to 3.5 cm in 
widest diameter. The rats were anesthetized with 90 mg/kg 
of ketamine (Vetalar, Aveco Corporation, Fort Dodge, Iowa) 
and 10 mg/kg of xylazine (Rompun, Mobay Corporation, 
Shawnee, Kans.) intraperitoneally. Following the insertion 
of an intravenous catheter in the tail vein, each animal was 
placed in supine (normal rats) or prone (tumor-bearing rats) 
position in the center of the coil. Coronal and axial T1 
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weighted images were obtained of each animal using a spin 
echo pulse sequence with the following parameters: TR300 
msec, TE 15 msec, slice thickness 5 mm, matrix 128x256, 
field of view 10 cm, 4 excitations and no phase wrap. Next, 
17 umol/kg of the Gd(III)texaphyrin complex dissolved in 
normal saline was infused at a rate of 0.25 ml/min intrave 
nously and repeat images were obtained at 10-15 minutes 
post contrast. One tumor-bearing rat was studied at 6 and 28 
hours post-contrast. All tuning parameters and the rats' 
positions were kept identical in the pre and post contrast 
SCS. 
Image Analysis: Operator defined regions of interest 
(ROI) measurements were made on axial slices of all pre and 
10-15 minutes post contrast studies. Regions in which 
measurements were made included the right lobes of the 
livers and the whole kidneys in the normal rats and the 
whole tumor in tumor-bearing rats. In addition, large ROI's 
of background air were measured for standardization pur 
poses. Standardized signal intensities (SSI) were calculated 
as follows: signal intensity (SI) of organ/SI air. An unpaired 
Student's t test was used to compare pre contrast and post 
contrast SSIs. 
Toxicity: At 24 hours, there were no deaths in the mice 
injected i.p. although those receiving the highest dose (312.5 
umol/kg) appeared lethargic. Autopsies of two mice from 
each dosage group revealed some edema and pallor of the 
liver and kidneys in the two groups receiving the highest 
doses (312.5 and 156.3 umol/kg). Autopsies from the 
remaining groups were normal. At 48 hours, the remaining 
mice (n=3 in each dosage group) in the two highest dosage 
groups died. The animals in the three lower dosage groups 
demonstrated no morbidity. There was no mortality or 
evidence of morbidity in the rats during the month of 
observation after scanning. 
Enhancement: Liver SSI increased by 81.7% (p<0.001), 
kidney by 114.9% (p<0.001) and tumor by 49.7% (p<0.02) 
from pre to 10-15 minutes post contrast. There was no 
significant difference in enhancement between the right and 
left lobe of the liver and between the two kidneys. Pre 
contrast, tumor parenchyma appeared homogeneous and of 
an intensity similar to adjacent muscle. Post contrast, tumor 
tissue demonstrated a mottled pattern of enhancement and 
was easily distinguished from adjacent tissues. The MRI 
appearance reflected the heterogeneous appearance of the 
tumor grossly which consists of necrotic tissue surrounded 
by viable stroma. In addition, in the one animal studied at 6 
and 28 hours post contrast, there was visible tumor enhance 
ment throughout the study period. The pattern of enhance 
ment, however, changed over time, with enhancement start 
ing at the edges of the tumor initially and including the 
center by 28 hours. 
These results show that the T2B2 gadolinium complex is 
an hepatic, renal and tumor-specific contrast agent. The 
agent was found to have relatively low toxicity in rodents. 
Intravenous administration resulted in statistically signifi 
cant hepatic, renal and tumor enhancement in rats within 
10-15 minutes with persistence of tumor enhancement for 
up to 28 hours. The early enhancement of tumor edges may 
represent contrast localization in areas of viable tumor. The 
later appearance of the tumor probably was caused by 
passive diffusion of some of the agent into central necrotic 
areas. It is unclear whether a selective transport or passive 
diffusion mechanism is responsible for initial tumor 
enhancement with GD(III)texaphyrin and whether intracel 
lular binding to peripheral-type benzodiazepene receptors 
occurs. The tumor could be differentiated from adjacent 














The chemical properties of this texaphyrin class of mac 
rocyclic ligands can be varied by peripheral substitution, 
which would allow biological properties to be optimized in 
terms of biodistribution, pharmacokinetics and toxicity. 
Magnetic Resonance Imaging of Atheroma. 




22(25),23-tridecaene shows accumulation in human 
cadaveric aorta. Two aortas obtained from autopsies were 
examined using magnetic resonance imaging before and 
after incubation in vitro for 15 minutes with the gadolinium 
complex of B2T2. Selective labeling of the endothelial cell 
surface and atheromas plaque relative to surrounding tissue 
was observed. These data indicate that the Gd(III)B2T2 
complex has utility in the non-invasive imaging of 
atheroma. 
Magnetic Resonance Imaging of the Upper GI Tract. The 
gadolinium complex of B2T2 (4,5-diethyl-10,23-dimethyl 
9,24bis-(3-hydroxypropyl)-16,17-(3 hydroxypropyloxy), 
13,20,25,26.27-pentaazapentacyclo[20.2.1.1.1.0'' 
heptacosa-1,3,5,7,9,11 (27),12,14(19), 15, 17.20,22(25),23 
tridecaene shows accumulation in the upper GI tract, 
especially the stomach, as determined by magnetic reso 
nance imaging. 
Magnetic Resonance Imaging of a Carcinoma Implanted 
in Rabbit Thigh Muscle. A rabbit bearing a transplanted V2 
carcinoma in thigh muscle was administered 5 umol 
Gd(III)B2T2 (acetate) per kg body weight. Axial MRI 
scans were made before (37A) 30 minutes (37B) and 3 hours 
(37C) after administration. The pulsing sequences used were 
conventional spin echo sequences TR/TE=300/15, 16 KHz., 
3 mm slice thickness and 256x192 matrix, 2 NEX, satura 
tion inferiorly and superiorly with no phase rap. 
Image enhancement of the implanted V2 carcinoma was 
achieved at doses as low as 5umol/kg (FIGS. 37A, 37B and 
37C) and viable liver image augmentation was obtained 
when using doses as low as 2 umol/kg. It is clear that 
Gd(III)B2T2 is able to localize in hypoxic areas of tumors 
as seen in the photographs of FIGS. 37A, 37B and 37C. No 
signs of acute toxicity were observed in any of these studies 
and no serious toxicity has been observed in healthy rats 
given daily 40 mol/kg doses of GdB2T2(acetate). Thus, 
the quantities needed for tumor and target organ enhance 
ment appear to be safe. 
Fluorescence imaging. A metal-free texaphyrin such as 
the ring-N derivative of texaphyrin shown in FIG. 20 is 
preferred for fluorescence imaging since the presence of a 
metal decreases the fluorescence of texaphyrins (Sessler et 
al., 1991). The fluorescence emission occurs 20 mm farther 
to the red wavelengths in relation to the absorbing wave 
lengths. Fluorescence may be useful in the imaging of skin 
tumors or in localization using fiber optics. 
Gamma irradiation for localization. Standard radiowave 
protons are used for magnetic resonance imaging, however, 
photons in several regions of the electromagnetic spectrum 
are suitable for medical imaging. Gamma-ray photons are 
used for position emission tomography (PET) and single 
photon emission computed tomography (SPECT); x-ray 
photons are used for conventional radiography, computed 
tomography, digital subtraction angiography (DSA) and 
iodine K-edge dichromography (ID). The use of internal 
x-ray emitting isotopes is discussed in Example 10. 
EXAMPLE 12 
Radiation Sensitization of Tumor Cells Using Gadolinium 
Texaphyrin 
This example describes the use of GdT2B2 as a radiosen 
sitizer to enhance the radiolysis of a mouse L1210 leukemia 
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cell line. Where GdTX is referred to in the drawings, the 
texaphyrin metal complex GdT2B2 was used. The presence 
of the metal is not important for the radiosensitization 
properties of texaphyrins, however, the metal contributes 
stability to the texaphyrin complex. 
Oxygen is the ultimate electron acceptor in physiological 
systems. However, the texaphyrins of the present invention 
have a redox potential below that of oxygen. All reductants 
will reduce texaphyrin, even superoxide. 
e =-2.80 V. 
Porphyrin=-0.6 to -1.8 V. 
Quinone= -0.2 to -1.0 V. 
O=-0.18 V. 
GdTXPO = +0.08 V. 
Therefore, gadolinium texaphyrin 'soaks up' electrons 
readily, and prevents them from neutralizing hydroxyl radi 
cals. This advantageous low redox potential of gadolinium 
texaphyrin confers a degree of specificity to radiation dam 
age using texaphyrin; in the absence of texaphyrin, hydroxyl 
radicals and solvated electrons recombine and little radiation 
damage occurs, in the presence of texaphyrin, hydroxyl 
radicals are free to do their damage. Furthermore, the 
trapping of electrons by texaphyrin prevents the Solvated 
electrons from interacting with the hydroxyl radical-induced 
damage site to repair the damage. 
A second mechanism by which texaphyrin exerts radia 
tion damage is demonstrated by experiments carried out in 
isopropanol. When an aqueous solution of isopropanol is 
irradiated, a proton is lost from the center carbon atom 
generating an isopropanol radical. The proton combines 
with a hydroxyl radical formed from water and neutralizes 
it. Therefore, all radiation products in an isopropanol solu 
tion are reducing radicals and isopropanol provides an 
appropriate environment for pulse radiolysis experiments. 
Experimental Conditions. Pulse radiolysis studies were 
made with the CFKR 4 MeV Van der Graaff electron beam 
accelerator. For reduction studies, GdT2B2 was dissolved in 
purified water containing phosphate buffer (2 mM, pH 7) 
and propan-2-ol (2M) so as to give a 100 uM solution. The 
solution was purged thoroughly with N before exposure to 
the ionizing pulse. The course of reaction was followed by 
optical spectroscopy. In separate studies, the solution was 
purged with pre-analyzed mixtures of N, and O. The 
radiation dose was measured by the thiocyanate dosimeter. 
The successive reduction of GdT2B2 was achieved by 
exposure of a solution to a series of bursts of ionizing 
radiation. Each burst consisted of 20 individual pulses from 
the accelerator and the course of reaction was followed by 
optical absorption spectroscopy. Composition of the solution 
was as above. 
For cytotoxicity studies, the radiation source was a Phil 
lips 50 KVP constant potential X-ray generator, model 
120.102.1 equipped with a Machlett OEG60 X-ray tube. 
Dosimetry was made with the Friecke dosimeter. This 
system delivers 110 Gy perminute into a target area of about 
2 cm diameter. Samples were contained in petri dishes 
mounted into a 12 well tray. Three unirradiated dishes and 
3 dishes containing cells without GdT2B2 served as control 
experiments. Six dishes containing cells and GdT2B2 were 
exposed to radiation for a predetermined period. A mechani 
cal arm moved the tray after each exposure. After radiolysis, 
cells were incubated for 24 hours and cell viability was 
established by both methyl red concentration and trypan 
blue exclusion methods using conventional cell counting 
techniques. All experiments were conducted with log phase 
cells (5x105 cells per mL). Mouse leukemia Ll210 cells 














A stock solution of GdT2B2 (1 mM) was prepared in 
purified water and small aliquots were added to cell suspen 
sions (5x10 cell per mL). The mixture was incubated for 1 
hour at 37° C. before being isolated, washed, and resus 
pended in nutrient solution. In most cases, the concentration 
of GdT2B2 was 80 M as measured by absorption spec 
troscopy. 
Radiation-induced cleavage of intracellular DNA (or 
RNA) was measured by alkaline elution chromatography. 
Polyvinylchloride filters (pore size 2 pm) were used. 
Samples were exposed to a total of 20 Gy radiation. 
Results. Pulse radiolysis experiments carried out with 
GdTXP in aqueous isopropanol are demonstrated in FIGS. 
31, 32A and 32B. FIG. 31 demonstrates GdTXP anion 
formation. FIG. 32A demonstrates the anion decay in an 
oxygen free solution and in 32B, decay in the presence of 
O. The data indicate the remarkable stability of the GdTXP 
anion and demonstrate that GdTXP does not pass its elec 
trons to oxygen, nor is it affected by the presence of oxygen. 
The data suggest the following intermediate radiolysis prod 
lucts for GdTXP: 
TABLE 1. 
Pulse Radiolysis in Aqueous Isopropanol 
GdTXP + e - G GdTXP 
<2 ms or rearrangement) 
H 
GdTXP +GdTXPH2 <- (2) GdTXP (H) 
very slow 
The GdTXP anion has a half life of less than 2 milli 
seconds, it picks up a proton or rearranges to the texaphyrin 
radical, GdTXP(H), which has significant stability and a 
relatively long half life, greater than 100 milliseconds and 
possibly as long as 2 seconds. 
A G value is defined as a radiation chemical yield. The 
radiation chemical yield of each of the radiolysis products of 
water is: HO, 2.8; H, 0.4; and e, 2.8. Therefore, the 
radiation chemical yield for water is 6, i.e., the G value is 6. 
A gamma radiolysis experiment in aqueous isopropanol for 
GdTXP demonstrated a G value of 2.8. One-half of the 
radiation equivalents are lost, probably because two 
GdTXP(H) radicals are reacting together to form GdTXP 
and GdTXPH. These data indicate that the GdTXP(H) 
radical is reactive, which is desirable for a radiosensitizer 
since a completely stable radical is not useful. The radical 
reacts with itself when it is the only species present (as in 
these experiments in isopropanol) but will react with neigh 
boring molecules in a physiological system as presented in 
FIG. 33. 
Data in FIG. 33 present the rate constant for the reaction 
of the GdTXP(H) radical with cytosine, one of the four 
nucleotide bases of DNA and RNA. It appears that 
GdTXP(H) is forming a covalent bond with cytosine, this 
reaction would probably inactivate the nucleic acid to which 
it bound. 
Gadolinium texaphyrin, therefore, has three advantageous 
properties for use as a radiosensitizer: 
i) the low redox potential of GdTXP causes solvated 
electrons to flow to GdTXP, allowing OH to do its 
damage, 
ii) the GdTXP(H) radical is relatively stable, yet reacts 




iii) the GdTXP may be particularly effective for treating 
the hypoxic areas of solid tumors because of intrinsic 
biolocalization and its indifference to the presence of 
O2. 
FIG.34 presents data from an experiment in which mouse 
Ll210 cells were exposed to 20 M GdTXP and radiation. 
The control curve represents cell kill in the absence of 
GdTXP, the curve labeled GdTXP represents cell kill in the 
presence of GdTXP. A sensitizer enhancement ratio (SER) is 
the ratio of the dose needed to kill 95% of the cells without 
GdTXP divided by the dose needed to kill 95% of the cells 
with GdTXP. If the sensitizer had no effect, the ratio would 
be 1.0, a very effective sensitizer would have a ratio of 3.0. 
The data of FIG. 34 indicate that at 20 M, GdTXP has an 
SER of 1.62. (An SER above 1.5 is clinically significant.) 
The SER increases with increasing concentrations of 
GdTXP as indicated in FIG. 35. For example, at 80 M, the 
SER is greater than 2.2, indicating that the highest physi 
ological tolerable level of GdTXP is desirable for radiosen 
sitization purposes. 
Total nucleic acid samples obtained from L1210 cells 
exposed to a total of 20 Gy radiation and varying levels of 
GdTXP were passed through a size selection filter. The data 
of FIG. 36 indicate that no nucleic acid passed through the 
filter in the absence of GdTXP and that in the presence of 
GdTXP, nucleic acid was cleaved into fragments that passed 
through the filter. A larger amount of fragments was pro 
duced with higher levels of GdTXP exposure. Clearly, 
nucleic acid strand scission occurs as a result of radiation in 
the presence of GdTXP. It is probable that the hydroxyl 
radical is responsible for the strand scission. 
The radiosensitization properties of the texaphyrins 
described herein may allow reduced doses of radiation to be 
effective in treatment of an individual. Therefore, radiation 
side effects such as nausea and damage to normal cells may 
be lessened when treatment includes the use of texaphyrins 
of the present invention. Expected dose levels for an indi 
vidual may range from 2-8mg/kg administered for a period 
of 2 to 24 hours. 
EXAMPLE 13 
Photodynamic Therapy, In vitro and In vivo Experiments 
In vitro data and experiments. The lanthanum complex of 
B2T2 (4,5-diethyl-10,23-dimethyl-9,24-bis(3-hydroxypro 
pyl) -16, 17-(3-hydroxypropyloxy)-13,20,25,26,27-pen 
taazapentacyclo (20.2.1.1.1'.0']heptacosa-1,3,5,7, 
9, 11(27),12,14(19), 15, 17, 20,22(25),23-tridecaene 
(LaB2T2) was used at concentrations of 5.0, 1.0 or 0.1 
micromolar in tissue culture medium. The murine mammary 
carcinoma cell line designated EMT-6 was cultured in 
medium containing LaB2T2 for 1 hour or 3 hours in the 
dark. Experimental cultures were irradiated with 10 Joules/ 
cm using an arc lamp with a 750 nanometerband pass filter. 
Cell survival was measured using a cell cloning assay. There 
was no dark toxicity indicating that LaB2T2 had no direct 
toxicity to the cells. Cultures which were irradiated with the 
visible red light showed viabilities of 3%, 50% and 100% for 
concentrations of LaB2T2 of 5.0, 1.0 and 0.1 micromolar 
respectively. The results were similar for 1 and 3 hour 
incubation periods. The results established that LaB2T2 was 
phototoxic to these tumor cells in vitro. 
In vivo experiments. Murine adenocarcinoma cells were 
inoculated into both flanks of Balb/c mice. Four days later, 
palpable tumor masses were present on both flanks of the 
mice. Ten mg/kg of lutetium B2T2 (LuB2T2) in aqueous 














was irradiated with 500 Joules of Argon laser light at 746 
nanometers. The uninradiated tumor served as a control. 
Animals were monitored daily and tumor measurements 
were made using calipers. Following a single treatment, 
65% cell kill was estimated based on the reduction in size of 
the treated tumors. No phototoxicity of skin or normal 
tissues surrounding the tumors was observed indicating 
relatively selective uptake of the LuB2T2 in the tumors. This 
experiment established the in vivo photodynamic activity of 
LuB2T2 in vivo. 
The hydroxy-substituted texaphyrins can be conjugated to 
biological molecules, especially proteins of molecular 
weight greater than about 20,000 daltons, e.g. albumin and 
gamma globulin, in order to slow their clearance by the 
kidneys. A prolonged presence of these complexes in tissue 
may be desirable for photoirradiation purposes. The conju 
gation would be accomplished as described in Example 10 
for biomolecule conjugates. 
EXAMPLE 14 
Hydroxy-Substituted Texaphyrins for Radiosensitization 
and Localization followed by Radiotherapy and/or Photo 
dynamic Tumor Therapy for Tumor Destruction 
This example describes the use of hydroxy substituted 
texaphyrins in the localization, radiosensitization and 
destruction of tumor tissue. A water soluble hydroxy-sub 
stituted texaphyrin is administered to a host harboring 
benign or malignant tumor cells. The texaphyrin exhibits 
radiosensitization properties and selective biolocalization in 
benign or malignant tumor cells relative to surrounding 
tissue. Localization sites in the host are determined by 
reference to the texaphyrin using, for example, magnetic 
resonance imaging when a paramagnetic metal complex of 
texaphyrin is administered, fluorescence when a free-base 
texaphyrin is administered, or gamma body scanning when 
a gamma-emitting metal is complexed with the administered 
texaphyrin. A preferred paramagnetic metal is Gd (III). 
The inherent radiosensitization properties of the texaphy 
rins as described in Example 12 allow electromagnetic 
radiation to be more effective and selective when adminis 
tered in the vicinity of the texaphyrin metal complex. Lower 
doses of radiation may therefore be used. The radiation may 
be from an external source or may be from an internal 
source, such as a radiometal bound to a texaphyrin. 
Examples of a radiometal include 'Gd, In, or 'Y. 
Alternatively, a second texaphyrin metal complex having 
essentially identical biolocalization property and exhibiting 
the ability to generate singlet oxygen upon exposure to light 
is administered. The second texaphyrin metal complex is 
photoirradiated in proximity to the benign or malignant 
tumor cells, as in fiber optics, to cause tumor tissue destruc 
tion from the singlet oxygen produced. The detectable metal 
in the second texaphyrin metal complex is a diamagnetic 
metal, preferably La(III), Lu(III) or InCIII). 
A further embodiment is the use of a texaphyrin radiosen 
sitizer and a photosensitive texaphyrin for treatment. This 
molecule may be a single texaphyrin metal diamagnetic 
complex, since the metal is not important for radiosensiti 
zation. A synergistic killing of cells may then be achieved by 
the use of light for photodynamic therapy in combination 
with electromagnetic radiation. An alternative embodiment 
is a synergistic killing due to an intrinsic radiochelated 
texaphyrin and externally applied radiation. In vitro uses of 
the method of radiosensitization and radiation therapy 
include sterilizations, and in the treatment of bone marrow, 
transfused blood or transplanted organs. 
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Texaphyrin-metal complexes will be chosen which them 
selves show a high intrinsic biolocalization selectivity for 
tumors or neoplastic tissues. For example, the B2T2 Gd(III) 
complex demonstrates in vivo affinity for tissue high in lipid 
content, atheroma, the liver, kidneys and tumors. 
The hydroxy substituted texaphyrin complexes are good 
candidates for such biomedical radiosensitizers and photo 
sensitizers. They “soak up' electrons in an irradiated area 
allowing hydroxyl radicals to cause radiation damage, the 
texaphyrin radicals react covalently with neighboring mol 
ecules causing further radiation damage, they are easily 
available, have low intrinsic cytotoxicity, long wavelength 
absorption, generate singlet oxygen, are soluble in physi 
ological environments, have the ability to be conjugated to 
site specific transport molecules, have quick elimination, are 
stable and are easily subject to synthetic modification. 
Significant advantages to using texaphyrins for imaging and 
destruction of cells are i) one texaphyrin is used for both 
functions, ii) the inherent selective biolocalization and the 
potential for derivatization to enhance further localization, 
iii) due to the radiosensitization properties of texaphyrin, 
radiation is more effective and lower doses of radiation may 
be used, therefore, fewer side effects are experienced and iv) 
a metal complex is not necessary for radiosensitization. The 
present invention provides a method to "see" and "kill” 
particular cells with a single agent having biolocalization 
selectivity and radiation enhancing properties. 
The following references are incorporated in pertinent 
part by reference herein for the reasons Cited below. 
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What is claimed is: 
1. A water soluble compound retaining lipophilicity and 
having the structure: 
Nt 
wherein 
M is H, a divalent metal cation selected from the grou 
consisting of Ca, Mn, Co, Ni', Zn, Cd', 
Hg, Fe, Sm' and UO,' or a trivalent metal cation 
selected from the group consisting of Mn", Co, Ni", 
Fe", Hot, Ce"3. Y+ s In", Pr'3, Nd", Sm', Eut, 
Gd, Tb"3, Dy'3, Er", Tim', Ybt, Lu", La", and 
U+3; 
R and R are CHCH, R is CH3, R1, R5 and Rs are 
independently hydrogen, hydroxyl, alkyl, hydroxy 
alkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, carboxy 
alkyl, carboxyamidealkyl, antibody, a peptide having 
affinity for a biological receptor, a sapphyrin molecule, 
or a couple to an antibody, a peptide having affinity for 
a biological receptor, or a sapphyrin molecule, where at 
least one of R, Rs, and R is oxyhydroxyalkyl, sac 
charide, oxyalkyl, carboxyalkyl, carboxyamidealkyl, 
hydroxyalkyl, an antibody, a peptide having affinity for 
a biological receptor, a sapphyrin molecule, or a couple 
to an antibody, a peptide having affinity for a biological 
receptor, or a sapphyrin molecule, having at least one 
hydroxy substituent; and N is 0, 1 or 2. 
2. The water soluble compound of claim 1 where R is 
CHCHCONCH(CHOH), and Rs and R are OCH. 
3. The water soluble compound of claim 1 where R is 
CHCHCONCH(CHOH), and Rs and Rs are 
OCHCHCH-OH. 
4. The water soluble compound of claim 1 where R is 
CHCHCONCH(CHOH) and Rs and Rs are 
OCHCHOH. 
5. The water soluble compound of claim 1 where R is 
CHCHCONCH(CHOH), and Rs and R are 
O(CHCHO)CHCHOR', where n is an integer less than 
or equal to 10 and R is H or CH3. 
6. The water soluble compound of claim 1 where R is 
CHCHCONCH(CHOH), and Rs and R are indepen 
dently H or CH 
7. The water soluble compound of claim 1 where R is 
CHCHCONCH(CHOH), R is CH, and R is H, CH, 
OCH, OCHCHOH, OCHCHCH-OH, O 
O(CHCHO)CHCHOR, where n is an integer less than 
or equal to 10 and R is H or CH 
8. The water soluble compound of claim 1 where R is 
CHCHCONCCHCH-OH) and Rs and R are OCH. 
9. The water soluble compound of claim 1 where R is 





10. The water soluble compound of claim 1 where R is 
CHCHCONCCHCH-OH) and Rs and R are 
OCHCHOH. 
11. The water soluble compound of claim 1 where R is 
CHCHCONCCHCH-OH) and R and R are 5 
O(CHCHO)CH, CHOR, where n is an integer less than 
or equal to 10 and R' is H or CH 
12. The water soluble compound of claim 1 where R is 
CHCHCONCCHCH-OH) and Rs and R are indepen 
dently H or CH, 10 
13. The water soluble compound of claim 1 where R is 
CHCHCONCCHCH-OH), R is CH and R is H, CH, 
OCH, OCHCH,OH, OCHCH,CHOH, O 
O(CH2CH2O)CHCHOR, where n is an integer less than 
or equal to 10 and R' is H or CH. 15 
14. The water soluble compound of claim 1 where R is 
CHCHCONHCHCH(OH)CH(OH)CH(OH)CH(OH)CHOH 
and Rs and R are OCH 
15. The water soluble compound of claim 1 where R is 
CHCHCONHCHCH(OH)CH(OH)CH(OH)CH(OH)CHO 
and Rs and R are OCH2CH2CH2OH. 
16. The water soluble compound of claim 1 where R is 
CHCHCONHCHCH(OH)CH(OH)CH(OH)CH(OH)CHOH 
and Rs and R are OCHCHOH. 
17. The water soluble compound of claim 1 where R is 25 
CHCHCONHCHCH(OH)CH(OH)CH(OH)CH(OH)CHOH 
and R and R are O(CH2CH2)CHCHOR', where n is an 
integer less than or equal to 10 and R is H or CH. 
18. The water soluble compound of claim 1 where R is 
CHCH,CONHCHCH(OH)CH(OH)CH(OH)CH(OH)CHOR 
and Rs and R are independently H or CH. 
19. The water soluble compound of claim 1 where R is 
CHCH,CONHCHCH(OH)CH(OH)CH(OH)CH(OH) 
CHOH, R is CH, and R is H, CH, OCH, 
OCHCH-OH, OCHCHCHOH, or O(CHCHO)CH 35 
CHOR', where n is an integer less than or equal to 10 and 
R" is H or CH, 
20. The water soluble compound of claim 1 where R is 
CHCHCH-OH and Rs and R are OCH. 
21. The water soluble compound of claim 1 where R is 40 
CHCHCH-OH and Rs and R are OCH2CH2CH2OH. 
22. The water soluble compound of claim 1 where R is 
CHCHCH-OH and Rs and R are OCH2CH2OH. 
23. The water soluble compound of claim 1 where R is 
CHCHCHOH and R and R are 45 
O(CH2CH2)CHCHOR, where n is an integer less than 
or equal to 10 and R' is H or CHB. 
24. The water soluble compound of claim 1 where R is 
CHCHCH-OH and Rs and R are independently H or 
CH. 50 
25. The water soluble compound of claim 1 where R is 
CHCHCH-OH, R is CH, and R is H, CH, OCH, 
OCHCHOH, OCH,CH,CH,OH, O 
O(CHCHO)CHCHOR, where n is an integer less than 
or equal to 10 and R is H or CH 55 
26. The water soluble compound of claim 1 where R is 
CHCHCONHCHO and Rs and R are OCH. 
27. The water soluble compound of claim 1 where R is 
CHCHCONHCHO and Rs and R are 
OCHCHCHOH. 60 
28. The water soluble compound of claim 1 where R is 
CHCHCONHCHO and Rs and R are OCH2CH2OH. 
29. The water soluble compound of claim 1 where R is 
CHCHCONHCH, O, and Rs and R are 
O(CHCHO), CHCHOR, where n is an integer less than 65 
or equal to 10 and R is H or CH 
30. The water soluble compound of claim 1 where R is 
42 
CHCHCONHCHO and Rs and R are independently 
H or CH, 
31. The water soluble compound of claim 1 where R is 
CH2CH2CONHCHOs, Riis CH, and R is H, CH, 
OCH, OCH, CH,OH, OCHCHCHOH, or 
O(CHCHO)CHCHOR, where n is an integer less than 
or equal to 10 and R' is H or CH 
32. The water soluble compound of claim 1 where R is 
CHCHCOOCHO and Rs and R are OCH. 
33. The water soluble compound of claim 1 where R is 
CHCHCOOCHOs and Rs and R are 
OCHCHCHOH. 
34. The water soluble compound of claim 1 where R is 
CHCHCOOCHOs and R and R are OCHCH-OH. 
35. The water soluble compound of claim 1 where R is 
CHCHCOOCHOs and Rs and R are 
O(CHCHO), CHCHOR, where n is an integer less than 
or equal to 10 and R' is H or CH. 
36. The water soluble compound of claim 1 where R is 
CHCHCOOCHO and Rs and R are independently H 
or CH. 
37. ihe water soluble compound of claim 1 where R is 
CHCHCOOCHOs, R is CH, and R is H, CH, 
OCH, OCHCH OH, OCHCHCHOH, or 
O(CHCHO)CHCHOR, where n is an integer less than 
or equal to 10 and R is H or CH. 
38. The water-soluble compound of claim 1 wherein the 
Oxyhydroxyalkyl is Co-Ho-1-2.O.O. or OCo-Ho 
1)–2x)OO, where 
n is a positive integer from 1 to 10; 
x is zero or a positive integer less than or equal to n; and 
y is zero or a positive integer less than or equal to 
((2n+1)-2x). 
39. The water soluble compound of claim 1 wherein the 
oxyhydroxyalkyl or saccharide is CHOR, 
OCHOR or (CH2)COR where 
n is a positive integer from 1 to 10, 
y is zero or a positive integer less than ((2n+1)-q), 
q is zero or a positive integer less than or equal to 2n+1, 
R" is independently H, alkyl, hydroxyalkyl, saccharide, 
Co-Hoon-1-2O.O.O2CCon-Hcc2n+1)-2O.O. or 
N(R)OCCo-Ho-1-2O, O, where 
m is a positive integer from 1 to 10, 
w is zero or a positive integer less than or equal to m, 
z is zero or a positive integer less than or equal to 
((2m+1)-2w), 
R is Halkyl hydroxyalkyl or C.H.O.R, where 
m is a positive integer from 1 to 10, 
Z is zero or a positive integer less than ((2m+1)-r), 
ris zero or a positive integer less than or equal to 2m+1, 
and 
R’ is independently H, alkyl, hydroxyalkyl, or saccha 
ride. 
40. The water soluble compound of claim 1 wherein the 
carboxyamidealkyl is (CH2)CONHR", O(CH2)CONHR", 
(CH2)CONCR), or O(CH2)CONCR) where 
n is a positive integer from 1 to 10, 
R is independently H, alkyl, hydroxyalkyl, saccharide, 
Con-whom -1)-2O.O. O2CCon-Hoon-1-2.O.O. O 
N(R) OCCo-Ho-1-2O, O, where 
m is a positive integer from 1 to 10, 
w is zero or a positive integer less than or equal to n, 
Z is zero or a positive integer less than or equal to 
((2m+1)-2w), 




m is a positive integer from 1 to 10, 
z is zero or a positive integer less than ((2m+1)-r), 
r is zero or a positive integer less than or equal to 
2m+1, and 
R is independently H, alkyl, hydroxyalkyl, or sac 
charide. 
41. The water soluble compound of claim 1 wherein the 
boyalkyl is C.H.(2-1) OR or OC Ho-1-O-Ra 
Were 
n is a positive integer from 1 to 10; 
y is zero or a positive integer less than ((2n+1)-q), 
q is zero or a positive integer less than or equal to 2n+1, 
Re is (CH2)COR, (CH2)CONHR or 
(CH2)CONCR), where 
n is a positive integer from 1 to 10; 
R is independently H, alkyl, hydroxyalkyl, saccharide, 
Con-whom--1-2wow0. O2CCon-whom 1-2 
wOO or 
N(R)OCCo-Ho-1-2O.O., where m is a posi 
tive integer from 1 to 10, 
w is zero or a positive integer less than or equal to m, 
z is zero or a positive integer less than or equal to 
((2m+1)-2w), 
R is H, alkyl, hydroxyalkyl, or C.Hon. --OR, 
where 
m is a positive integer from 1 to 10, 
z is zero or a positive integer less than ((2m+1)-r), 
r is zero or a positive integer less than or equal to 
2m+1, and R is independently H, alkyl, hydroxy 
alkyl, or saccharide. 
42. The water soluble compound of claim 1 where R is 
CHCHCH-OH and Rs and R are 
O(CHCHO)CH.CHOR', where R is H or CH 
43. The water soluble compound of claim 1 where R is 
CHCHCHOH and Rs and R a 
O(CHCHO)CHCHOCH. 
44. The water soluble compound of claim 23 whereinn is 
2 and R is CH. 
45. The water soluble compound of claim 42, 43 or 44 
wherein M is Gd". 
46. The water soluble compound of claim 42, 43 or 44 
wherein M is Lu'. 
47. The water soluble compound of claim 1 where R is 
CHCHCH-OH and Rs and R are OCHCOOH or 
OCHCHCOOH. 
48. The water soluble compound of claim 1 where R is 











(CH(OH)CHOH: OCHCHC(CHOH); O 
OCHCHCOOCHC(CHOH). 
49. The water soluble compound of claim 1 wherein R is 
CHCHCHOH; R is (O)(CH2)CONHR, where m is 
zero or 1; n is zero, 1, 2, or 3; and R is an aminosugar, a 
polysaccharide, an oligosaccharide, or an oligopeptide; and 
R is H, OH, OCH, O(CH)OH, O(CH)OH, or COOH. 
50. The water soluble compound of claim 1 where R is 
CHCHCHOH; R is (O)(CH2)CONHR, where m is 
Zero or 1; n is zero, 1, 2, or 3; and R is glucosamine, 
galactosamine, mannosamine, poly-L-lysine, derivatized 
poly-L-lysine, (LysAla), (Lysieu Ala), polyglutamic acid, 
polyornithine, or heparin; and R is H, OH, OCH, 
O(CH),OH, O(CH),OH, or COOH. 
51. The water soluble compound of claim 49 or 50 where 
R is H. 
52. The water soluble compound of claim 1 were R is 
CH(CH2CH2O)CHCHOR, where n is an integerless 
than or equal to 10 and R is H or CH, and Rs and Rs are 
OCH, OCHCH-OH; OCHCHCHOH; 
O(CHCHO)CHCHOR, where n is an integer less than 
or equal to 10 and R is H or CH, or independently H or 
CH. 
53. The water soluble compound of claim 52 where Rs 
and R are OCH2CH2CH2OH. 
54. The water soluble compound of claim 1 where R is 
(CH),CONCR)R, where n is 1, 2, or 3, R is H or CH, and 
R is an aminosugar, a polysaccharide, an oligosaccharide, or 
an oligopeptide; and Rs and R are CH, OCH, 
O(CH)OH, or O(CH), OH. 
55. The water soluble compound of claim 1 where R is 
O(CH2)CONCR)R, where n is 1, 2, or 3, R is Hor CH, and 
R is glucosamine, galactosamine, mannosamine, poly-L- 
lysine, derivatized poly-L-lysine, (LySAla), (LysLeuAla), 
polyglutamic acid, polyornithine, or heparin; and Rs and R. 
are CH, OCH, O(CH),OH, or O(CH)OH. 
56. The water soluble compound of claim 1 where Rs and 
R are OCHCH-OHCHOH. 
57. The water soluble compound of claim 23 wherein M 
is Minor Mn. 
58. The water soluble compound of claim 43 wherein M 
is Mint’ or Mn. 
59. The water soluble compound of claim 1 where R is 
CHCH2CH2OH, Rs and R are OCH2CH2CH2OH, and M 
is Mn2 or Mn. 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 5,457, 183 
DATED October 10, 1995 
INVENTOR(S) : Jonathan L. Sessler Tarak D. Modiv Gregorv W. Hemi 
Wladimir Kral 
it is Certified that error appears in the above-indentified patent and that said Letters Patent is hereby 
Corrected as shown below: 
In claim 39, column 42, line 47, please insert -- -- between "alkyl" and "hydroxyalkyll. 
In claim 52, column 44, line 19, please delete "intergerless it 
and substitute therefor -- integer less -- 
In claim 17, column 41, line 27, please delete "CH" and 
substitute therefor -- CHott. 
In claim 23, column 41, line 46, please delete "CH" and 
substitute therefor -- Choir. 
In claim 23, column 41, line 47 please delete "CHB and 
substitute therefor -- CH, --. 
Signed and Sealed this 
Fifth Day of March, 1996 
(a teen 
BRUCE LEHMAN 

















UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO : 5,457,183 
DATED : October 10, 1995 
INVENTOR(S): Sessler, et al. 
It is certified that error appears in the above-identified patent and that said Letters Patent 
is hereby corrected as shown below: 
On the cover page, item (*) Notice: please correct the reference to the Terminal Disclaimer to 
read as follows: 
--The term of this patent shall not extend beyond the expiration date of Patent No. 5,252,720.-- 
At column 1, please replace the paragraph at lines 3-6 with the following: 
The government may own certain rights in the present invention pursuant to one or more 
of the following: National Institutes of Health Grants CA68682, Al28845 and Al33577; and 
National Science Foundation Grants CHE8552768 and CHE9122161.-- 
Signed and Sealed this 
Sixth Day of June, 2000 
Q. ToDD DICKINSON 
Director of Patents and Trademarks Attesting Officer 
  
